<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Front Oncol</journal-id><journal-id journal-id-type="pmc-domain-id">1755</journal-id><journal-id journal-id-type="pmc-domain">frontonco</journal-id><journal-id journal-id-type="publisher-id">Front. Oncol.</journal-id><journal-title-group><journal-title>Frontiers in Oncology</journal-title></journal-title-group><issn pub-type="epub">2234-943X</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC9731832</article-id><article-id pub-id-type="pmcid-ver">PMC9731832.1</article-id><article-id pub-id-type="pmcaid">9731832</article-id><article-id pub-id-type="pmcaiid">9731832</article-id><article-id pub-id-type="pmid">36508554</article-id><article-id pub-id-type="doi">10.3389/fonc.2022.1046307</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Oncology</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Incidence and survival of lymphoid neoplasms in Spain, 2002-2013: A population-based study from the Spanish Network of Cancer Registries (REDECAN)</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Pla</surname><given-names initials="C">Cl&#224;udia</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1818625"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Solans</surname><given-names initials="M">Marta</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2067054"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ameijide</surname><given-names initials="A">Alberto</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sanvisens</surname><given-names initials="A">Arantza</given-names></name><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><xref rid="aff6" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Carulla</surname><given-names initials="M">Mari&#224;</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rojas</surname><given-names initials="MD">Mar&#237;a Dolores</given-names></name><xref rid="aff7" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Alem&#225;n</surname><given-names initials="MA">Mar&#237;a Araceli</given-names></name><xref rid="aff7" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>S&#225;ez-Lloret</surname><given-names initials="I">Isabel</given-names></name><xref rid="aff8" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>D&#237;az-del-Campo</surname><given-names initials="C">Cristina</given-names></name><xref rid="aff9" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Marcos-Navarro</surname><given-names initials="AI">Ana Isabel</given-names></name><xref rid="aff10" ref-type="aff">
<sup>10</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sainz-de-Aja</surname><given-names initials="L">Leire</given-names></name><xref rid="aff11" ref-type="aff">
<sup>11</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Aizpurua-Atxega</surname><given-names initials="A">Amaia</given-names></name><xref rid="aff11" ref-type="aff">
<sup>11</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lopez-de-Munain</surname><given-names initials="A">Arantza</given-names></name><xref rid="aff11" ref-type="aff">
<sup>11</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>S&#225;nchez</surname><given-names initials="MJ">Maria-Jos&#233;</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="aff12" ref-type="aff">
<sup>12</sup>
</xref><xref rid="aff13" ref-type="aff">
<sup>13</sup>
</xref><xref rid="aff14" ref-type="aff">
<sup>14</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Perucha</surname><given-names initials="J">Josefina</given-names></name><xref rid="aff15" ref-type="aff">
<sup>15</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Franch</surname><given-names initials="P">Paula</given-names></name><xref rid="aff16" ref-type="aff">
<sup>16</sup>
</xref><xref rid="aff17" ref-type="aff">
<sup>17</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chirlaque</surname><given-names initials="MD">Mar&#237;a-Dolores</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="aff18" ref-type="aff">
<sup>18</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Guevara</surname><given-names initials="M">Marcela</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="aff19" ref-type="aff">
<sup>19</sup>
</xref><xref rid="aff20" ref-type="aff">
<sup>20</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1953290"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Galceran</surname><given-names initials="J">Jaume</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Merino</surname><given-names initials="S">Susana</given-names></name><xref rid="aff21" ref-type="aff">
<sup>21</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Marcos-Gragera</surname><given-names initials="R">Rafael</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><xref rid="aff6" ref-type="aff">
<sup>6</sup>
</xref><xref rid="aff22" ref-type="aff">
<sup>22</sup>
</xref></contrib><contrib id="collab1" contrib-type="author"><collab>REDECAN working group<contrib-group><contrib contrib-type="collab"><name name-style="western"><surname>RM-G</surname><given-names initials=""/></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Puigdemont</surname><given-names initials="M">Montse</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Vila</surname><given-names initials="AV">Anna Vidal</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>AS</surname><given-names initials=""/></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Castillo-Bonilla</surname><given-names initials="A">Andr&#233;s</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>MC</surname><given-names initials=""/></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>AA</surname><given-names initials=""/></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>CP</surname><given-names initials=""/></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>JG</surname><given-names initials=""/></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>AL-d-M</surname><given-names initials=""/></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Sancho</surname><given-names initials="P">Patricia</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Iruretagoyena</surname><given-names initials="ML">Mar&#237;a Luisa</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Ram&#237;rez</surname><given-names initials="C">Cristina</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>SM</surname><given-names initials=""/></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Garc&#237;a</surname><given-names initials="VM">Virginia Men&#233;ndez</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Camblor</surname><given-names initials="MR">Marta Rodr&#237;guez</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>de Castro</surname><given-names initials="V">Visitaci&#243;n</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Cruz</surname><given-names initials="MDL">Marta De La</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Bidaurrazaga</surname><given-names initials="J">Joseba</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Gregori</surname><given-names initials="CS">Consol Sabater</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Lloret</surname><given-names initials="IS">Isabel S&#225;ez</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Batll&#233;s</surname><given-names initials="AV">Ana Vizca&#237;no</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Herrero</surname><given-names initials="XP">Xavier Pe&#241;alver</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>CD-d-C</surname><given-names initials=""/></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>AM</surname><given-names initials=""/></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Chillar&#243;n</surname><given-names initials="RJ">Rosario Jimenez</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>AA</surname><given-names initials=""/></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>MDR</surname><given-names initials=""/></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Miguel</surname><given-names initials="ED">Emilio De</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Gabas</surname><given-names initials="MC">Mar&#237;a Carmen</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>MJS</surname><given-names initials=""/></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Chang-Chan</surname><given-names initials="DYL">Daysi Yoe-Ling</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Barranco</surname><given-names initials="MR">Miguel Rodr&#237;guez</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Palacios</surname><given-names initials="MI">Mar&#237;a Isabel</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Ramalle</surname><given-names initials="E">Enrique</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Franch</surname><given-names initials="P">Paula</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Armengol</surname><given-names initials="PR">Patricia Ruiz</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Contador</surname><given-names initials="CS">Carmen S&#225;nchez</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>MDC</surname><given-names initials=""/></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Gil</surname><given-names initials="AS">Antonia S&#225;nchez</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Vaamonde</surname><given-names initials="RJ">Ricardo Jos&#233;</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>MG</surname><given-names initials=""/></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Ardanaz</surname><given-names initials="E">Eva</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>MAA</surname><given-names initials=""/></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Vel&#225;zquez</surname><given-names initials="LO">Leonor Olga</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Marrero</surname><given-names initials="MMR">Mar&#237;a Magdalena Ramos</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Guti&#233;rrez</surname><given-names initials="P">Pilar</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>&#193;lamo</surname><given-names initials="R">Rufino</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Est&#233;vez</surname><given-names initials="L">Lorena</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Ca&#241;ete</surname><given-names initials="A">Adela</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Pardo</surname><given-names initials="E">Elena</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Bonet</surname><given-names initials="RP">Rafael Peris</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Gregori</surname><given-names initials="CS">Consol Sabater</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Batll&#233;s</surname><given-names initials="AV">Ana Vizcaino</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Vich.</surname><given-names initials="FA">Fernando Almela</given-names></name></contrib></contrib-group></collab></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>Tarragona Cancer Registry, Cancer Epidemiology and Prevention Service, Sant Joan de Reus University Hospital</institution>, <addr-line>Reus</addr-line>, <country>Spain</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>Institut d&#8217;Investigaci&#243; Sanit&#224;ria Pere Virgili (IISPV), Reus</institution>, <addr-line>Tarragona</addr-line>, <country>Spain</country>
</aff><aff id="aff3">
<sup>3</sup>
<institution>Research Group on Statistics, Econometrics and Health (GRECS), University of Girona</institution>, <addr-line>Girona</addr-line>, <country>Spain</country>
</aff><aff id="aff4">
<sup>4</sup>
<institution>Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP)</institution>, <addr-line>Madrid</addr-line>, <country>Spain</country>
</aff><aff id="aff5">
<sup>5</sup>
<institution>Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Catalan Institute of Oncology, Girona Biomedical Research Institute Dr. Josep Trueta (IDIBGI)</institution>, <addr-line>Girona</addr-line>, <country>Spain</country>
</aff><aff id="aff6">
<sup>6</sup>
<institution>Josep Carreras Leukaemia Research Institute</institution>, <addr-line>Girona</addr-line>, <country>Spain</country>
</aff><aff id="aff7">
<sup>7</sup>
<institution>Canary Islands Cancer Registry, Public Health Directorate, Canary Islands Government</institution>, <addr-line>Las Palmas</addr-line>, <country>Spain</country>
</aff><aff id="aff8">
<sup>8</sup>
<institution>Castell&#243;n Cancer Registry, Directorate General of Public Health and Addictions, Valencian Government</institution>, <addr-line>Castell&#243;n</addr-line>, <country>Spain</country>
</aff><aff id="aff9">
<sup>9</sup>
<institution>Ciudad Real Cancer Registry, Health and Social Welfare Authority</institution>, <addr-line>Castile&#8722;La Mancha</addr-line>, <country>Spain</country>
</aff><aff id="aff10">
<sup>10</sup>
<institution>Cuenca Cancer Registry, Health and Social Welfare Authority</institution>, <addr-line>Castile&#8722;La Mancha</addr-line>, <country>Spain</country>
</aff><aff id="aff11">
<sup>11</sup>
<institution>Basque Country Cancer Registry, Basque Government</institution>, <addr-line>Vitoria-Gasteiz</addr-line>, <country>Spain</country>
</aff><aff id="aff12">
<sup>12</sup>
<institution>Granada Cancer Registry, Andalusian School of Public Health (EASP), Instituto de Investigaci&#243;n Biosanitaria Ibs.GRANADA, University of Granada</institution>, <addr-line>Granada</addr-line>, <country>Spain</country>
</aff><aff id="aff13">
<sup>13</sup>
<institution>Instituto de Investigaci&#243;n Biosanitaria Ibs.GRANADA</institution>, <addr-line>Granada</addr-line>, <country>Spain</country>
</aff><aff id="aff14">
<sup>14</sup>
<institution>Department of Preventive Medicine and Public Health, University of Granada</institution>, <addr-line>Granada</addr-line>, <country>Spain</country>
</aff><aff id="aff15">
<sup>15</sup>
<institution>La Rioja Cancer Registry, Epidemiology and Health Prevention Service</institution>, <addr-line>Logro&#241;o</addr-line>, <country>Spain</country>
</aff><aff id="aff16">
<sup>16</sup>
<institution>Mallorca Cancer Registry, Public Health and Participation Department</institution>, <addr-line>Palma de Mallorca</addr-line>, <country>Spain</country>
</aff><aff id="aff17">
<sup>17</sup>
<institution>Health Research Institute of the Balearic Islands (IdISBa)</institution>, <addr-line>Palma de Mallorca</addr-line>, <country>Spain</country>
</aff><aff id="aff18">
<sup>18</sup>
<institution>Department of Epidemiology, Regional Health Authority, Instituto Murciano de Investigaci&#243;n Biosanitaria (IMIB)-Arrixaca, Murcia University</institution>, <addr-line>Murcia</addr-line>, <country>Spain</country>
</aff><aff id="aff19">
<sup>19</sup>
<institution>Navarra Cancer Registry, Navarra Public Health Institute</institution>, <addr-line>Pamplona</addr-line>, <country>Spain</country>
</aff><aff id="aff20">
<sup>20</sup>
<institution>Epidemiology and Public Health Area, Navarra Institute for Health Research (IdiSNA)</institution>, <addr-line>Pamplona</addr-line>, <country>Spain</country>
</aff><aff id="aff21">
<sup>21</sup>
<institution>Department of Health, Asturias Cancer Registry, Public Health Directorate</institution>, <addr-line>Asturias</addr-line>, <country>Spain</country>
</aff><aff id="aff22">
<sup>22</sup>
<institution>University of Girona</institution>, <addr-line>Girona</addr-line>, <country>Spain</country>
</aff><author-notes><fn fn-type="edited-by"><p>Edited by: Valentin Garcia-Gutierrez, Ram&#243;n y Cajal University Hospital, Spain</p></fn><fn fn-type="edited-by"><p>Reviewed by: John L Vaughn, Yale New Haven Health System, United States; Rafael Dezen Gaiolla, Hospital das Cl&#237;nicas da Faculdade de Medicina de Botucatu, Brazil</p></fn><corresp id="fn001">*Correspondence: Cl&#224;udia Pla, <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:claudia.pla@salutsantjoan.cat">claudia.pla@salutsantjoan.cat</email></corresp><fn fn-type="other" id="fn002"><p>This article was submitted to Hematologic Malignancies, a section of the journal Frontiers in Oncology</p></fn></author-notes><pub-date pub-type="epub"><day>24</day><month>11</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>12</volume><issue-id pub-id-type="pmc-issue-id">400062</issue-id><elocation-id>1046307</elocation-id><history><date date-type="received"><day>16</day><month>9</month><year>2022</year></date><date date-type="accepted"><day>27</day><month>10</month><year>2022</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>01</month><year>2022</year></date></event><event event-type="pmc-live"><date><day>10</day><month>12</month><year>2022</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2022-12-13 06:10:12.247"><day>13</day><month>12</month><year>2022</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2022 Pla, Solans, Ameijide, Sanvisens, Carulla, Rojas, Alem&#225;n, S&#225;ez-Lloret, D&#237;az-del-Campo, Marcos-Navarro, Sainz-de-Aja, Aizpurua-Atxega, Lopez-de-Munain, S&#225;nchez, Perucha, Franch, Chirlaque, Guevara, Galceran, Merino, Marcos-Gragera and REDECAN working group</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Pla, Solans, Ameijide, Sanvisens, Carulla, Rojas, Alem&#225;n, S&#225;ez-Lloret, D&#237;az-del-Campo, Marcos-Navarro, Sainz-de-Aja, Aizpurua-Atxega, Lopez-de-Munain, S&#225;nchez, Perucha, Franch, Chirlaque, Guevara, Galceran, Merino, Marcos-Gragera and REDECAN working group</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fonc-12-1046307.pdf"/><abstract><sec><title>Introduction</title><p>The aim of this study was to describe incidence, incidence trends and survival patterns of lymphoid neoplasms (LNs) and its subtypes in Spain in the period 2002-2013 using data from the Spanish Network of Cancer Registries (REDECAN).</p></sec><sec><title>Materials and Methods</title><p>Data were extracted from 13 Spanish population-based cancer registries. LNs incident cases were codified using the International Classification of Diseases for Oncology, third edition (ICD-O-3) and grouped according to the WHO 2008 classification. Age-standardized incidence rates to the 2013 European standard population (ASIRe) were obtained. Poisson regression models were used to analyze trends in incidence rates and estimate the annual percentage change (APC) for each subtype. The number of cases in Spain for 2023 was estimated by applying the estimated age-specific rates for the year 2023 to the 2023 Spanish population. Observed survival (OS) was estimated by the Kaplan-Meier method and net survival (NS) by the Pohar-Perme method. Sex- and age-specific estimates of 5-year NS were calculated, as well as its changes according to two periods of diagnosis (2002-2007 and 2008-2013).</p></sec><sec><title>Results</title><p>LNs accounted for 69% (n=39,156) of all hematological malignancies (n=56,751) diagnosed during the period of study. Median age at diagnosis was 67 years (interquartile range (IQR) = 52-77). The overall ASIRe was 34.23 (95% confidence interval (CI): 33.89, 34.57) and showed a marked male predominance in almost all subtypes (global sex ratio = 1.45). During the study period, incidence trends of LNs remained stable (APC: 0.3; 95% CI: -0.1, 0.6), nevertheless some subtypes showed statistically significant variations, such as LNs NOS category (APC: -5.6; 95% CI: -6.8, -4.3). Around 17,926 new cases of LNs will be diagnosed in 2023 in Spain. Survival rates differed considerably across age-groups, while they were similar between men and women. Five- year NS was 62.81% (95% CI: 62.1, 63.52) for all LNs, and varied widely across LNs subtypes, ranging from 39.21% to 90.25%. NS for all LNs improved from the first period of diagnosis to the second one, being 61.57% (95% CI: 60.56, 62.61) in 2002-2007 and 64.17% (95% CI: 63.29, 65.07) in 2008-2013.</p></sec><sec><title>Conclusions</title><p>This study presents the first complete and extensive population-based analysis of LNs incidence and survival in Spain. These population-based data provide relevant information to better understand the epidemiology of LNs in Southern Europe and it features some useful points for public health authorities and clinicians. However, additional improvements regarding the registration of these hematological neoplasms can be implemented.</p></sec></abstract><kwd-group><kwd>lymphoid neoplasms</kwd><kwd>trends</kwd><kwd>incidence</kwd><kwd>survival</kwd><kwd>population-based</kwd><kwd>Spain</kwd></kwd-group><funding-group><award-group><funding-source id="cn001"><institution-wrap><institution>Institut de Recerca contra la Leuc&#232;mia Josep Carreras
</institution><institution-id institution-id-type="doi">10.13039/501100020618</institution-id></institution-wrap></funding-source></award-group></funding-group><counts><fig-count count="3"/><table-count count="3"/><equation-count count="0"/><ref-count count="45"/><page-count count="13"/><word-count count="6425"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Hematological neoplasms are a group of diseases in which the hematopoietic system, the one in charge of the differentiation and proliferation of erythrocytes, thrombocytes, granulocytes and lymphocytes, is involved. The altered proliferation and/or differentiation of the different lineage precursors drives to a wide group of diseases with diverse etiology, presentation and outcomes, and depending on the lineage we find the first stratification of these neoplasms: myeloid neoplasms, lymphoid neoplasms (LNs) and histiocytic/dendritic neoplasms.</p><p>LNs, which comprise a heterogeneous group of more than 60 histological subtypes, are ranked as the 6<sup>th</sup> to 7<sup>th</sup> most common cancer worldwide (<xref rid="B1" ref-type="bibr">1</xref>). Broadly, they are grouped into four main categories: Hodgkin lymphoma, precursor lymphoid neoplasms, mature B-cell neoplasms, and mature T- and NK-cell neoplasms. Changes in our understanding of LNs have resulted in the continuous update of classification schemes over the past 60 years (<xref rid="B2" ref-type="bibr">2</xref>). The World Health Organization (WHO) with its first classification of tumors of hematopoietic and lymphoid tissues published in 2001 (<xref rid="B3" ref-type="bibr">3</xref>), and subsequently updated in 2008 (<xref rid="B4" ref-type="bibr">4</xref>), 2016 (<xref rid="B5" ref-type="bibr">5</xref>) and 2022 (<xref rid="B6" ref-type="bibr">6</xref>), is currently regarded as the gold standard for the diagnosis and research of LNs. Furthermore, the correspondence established between the WHO classification and the last editions of the International Classification of Diseases for Oncology (ICD-O-3) codes (<xref rid="B7" ref-type="bibr">7</xref>), has provided international standards for the registration and epidemiological surveillance of these diseases.</p><p>During the last decades, population-based data of LNs has become more available, with multiple studies from hematology-specialized registries (<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>) or large European and North American datasets (<xref rid="B10" ref-type="bibr">10</xref>&#8211;<xref rid="B14" ref-type="bibr">14</xref>). Specifically in Spain, however, few regional studies have reported incidence and survival data of LNs (<xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B16" ref-type="bibr">16</xref>), while there is a lack of subtype-specific data at a nationwide level. Therefore, the aim of this study was to describe incidence and survival patterns of LNs subtypes in Spain over the period 2002-2013, and to estimate the number of LNs expected in 2023, using data from the Spanish Network of Cancer Registries (REDECAN).</p></sec><sec sec-type="materials|methods" id="s2"><title>Materials and methods</title><sec id="s2_1"><title>Study population</title><p>Study data were extracted from 13 Spanish population-based cancer registries (PBCR) (Asturias, Canary Islands &#8211;Tenerife and Gran Canaria&#8211;, Castell&#243;n, Ciudad Real, Cuenca, Euskadi, Girona, Granada, La Rioja, Mallorca, Murcia, Navarra and Tarragona) which together cover 13 provinces and three islands. These PBCR, associated since 2010 in REDECAN (<xref rid="B17" ref-type="bibr">17</xref>), provided all LNs, both in pediatric and adult cases, registered from 2002 to 2013 (or the period available between these years) covering almost 26% of the total Spanish population (12,143,157 out of 47,129,783 inhabitants in January 2013) (<xref rid="B18" ref-type="bibr">18</xref>).</p><p>Quality indicators, which were defined based on the standards of the International Agency for Research on Cancer (IARC) (<xref rid="B19" ref-type="bibr">19</xref>), are detailed by PBCR in <xref rid="SM1" ref-type="supplementary-material">
<bold>Table S1</bold>
</xref> of the <xref rid="SM1" ref-type="supplementary-material">
<bold>Supplementary material</bold>
</xref>. Overall, 96.7% of the cases included were microscopically verified, 5.0% were not otherwise specified (NOS) cases and 1.1% were cases notified to the registry solely based on death certificates (DCO).</p></sec><sec id="s2_2"><title>Cases and groupings</title><p>Cases were codified using the ICD-O-3 (<xref rid="B7" ref-type="bibr">7</xref>) and grouped according to the WHO 2008 classification (<xref rid="B4" ref-type="bibr">4</xref>) (<xref rid="T1" ref-type="table">
<bold>Table&#160;1</bold>
</xref>). In brief, LNs were grouped into five broad categories: Hodgkin lymphomas, precursor lymphoid neoplasms, mature B-cell neoplasms, mature T-cell and NK-cell neoplasms and lymphoid neoplasms, NOS.</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table&#160;1</label><caption><p>Crude and age-adjusted incidence rates of lymphoid neoplasms diagnosed in Spain, 2002-2013.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Subtype</th><th valign="top" align="center" rowspan="1" colspan="1">ICD-O-3 codes</th><th valign="top" align="center" rowspan="1" colspan="1">N. of cases</th><th valign="top" align="center" rowspan="1" colspan="1">%</th><th valign="top" align="center" rowspan="1" colspan="1">Median Age</th><th valign="top" align="center" rowspan="1" colspan="1">CR95% CI</th><th valign="top" align="center" rowspan="1" colspan="1">ASIRe95% CI</th><th valign="top" align="center" rowspan="1" colspan="1">Sex ratio</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>Lymphoid neoplasm, total</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">
<bold>39,156</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>100.00</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>67</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>31.23 (30.92-31.54)</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>34.23 (33.89-34.57)</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>1.22</bold>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>1) Hodgkin lymphoma</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">
<bold>3,667</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>9.37</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>36</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>2.92 (2.83-3.02)</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>2.84 (2.74-2.93)</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>1.38</bold>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;1.1 Classical Hodgkin lymphoma</td><td valign="top" align="center" rowspan="1" colspan="1">9650-9655, 9661-9667</td><td valign="top" align="center" rowspan="1" colspan="1">3,455</td><td valign="top" align="center" rowspan="1" colspan="1">8.82</td><td valign="top" align="center" rowspan="1" colspan="1">36</td><td valign="top" align="center" rowspan="1" colspan="1">2.76 (2.66-2.85)</td><td valign="top" align="center" rowspan="1" colspan="1">2.67 (2.58-2.76)</td><td valign="top" align="center" rowspan="1" colspan="1">1.33</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;1.1.1 Lymphocyte-rich classical Hodgkin lymphoma</td><td valign="top" align="center" rowspan="1" colspan="1">9651</td><td valign="top" align="center" rowspan="1" colspan="1">202</td><td valign="top" align="center" rowspan="1" colspan="1">0.52</td><td valign="top" align="center" rowspan="1" colspan="1">43</td><td valign="top" align="center" rowspan="1" colspan="1">0.16 (0.14-0.18)</td><td valign="top" align="center" rowspan="1" colspan="1">0.16 (0.14-0.18)</td><td valign="top" align="center" rowspan="1" colspan="1">2.37</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;1.1.2 Nodular sclerosis classical Hodgkin lymphoma</td><td valign="top" align="center" rowspan="1" colspan="1">9663-9667</td><td valign="top" align="center" rowspan="1" colspan="1">1,906</td><td valign="top" align="center" rowspan="1" colspan="1">4.87</td><td valign="top" align="center" rowspan="1" colspan="1">31</td><td valign="top" align="center" rowspan="1" colspan="1">1.52 (1.45-1.59)</td><td valign="top" align="center" rowspan="1" colspan="1">1.43 (1.37-1.5)</td><td valign="top" align="center" rowspan="1" colspan="1">1.00</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;1.1.3 Mixed cellularity classical Hodgkin lymphoma</td><td valign="top" align="center" rowspan="1" colspan="1">9652</td><td valign="top" align="center" rowspan="1" colspan="1">727</td><td valign="top" align="center" rowspan="1" colspan="1">1.86</td><td valign="top" align="center" rowspan="1" colspan="1">45</td><td valign="top" align="center" rowspan="1" colspan="1">0.58 (0.54-0.62)</td><td valign="top" align="center" rowspan="1" colspan="1">0.58 (0.53-0.62)</td><td valign="top" align="center" rowspan="1" colspan="1">2.00</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;1.1.4 Lymphocyte-depleted classical Hodgkin lymphoma</td><td valign="top" align="center" rowspan="1" colspan="1">9653-9655</td><td valign="top" align="center" rowspan="1" colspan="1">96</td><td valign="top" align="center" rowspan="1" colspan="1">0.25</td><td valign="top" align="center" rowspan="1" colspan="1">52</td><td valign="top" align="center" rowspan="1" colspan="1">0.08 (0.06-0.09)</td><td valign="top" align="center" rowspan="1" colspan="1">0.08 (0.06-0.09)</td><td valign="top" align="center" rowspan="1" colspan="1">2.43</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;1.1.5 Classical Hodgkin lymphoma, NOS</td><td valign="top" align="center" rowspan="1" colspan="1">9650,9661-9662</td><td valign="top" align="center" rowspan="1" colspan="1">524</td><td valign="top" align="center" rowspan="1" colspan="1">1.34</td><td valign="top" align="center" rowspan="1" colspan="1">45</td><td valign="top" align="center" rowspan="1" colspan="1">0.42 (0.38-0.45)</td><td valign="top" align="center" rowspan="1" colspan="1">0.42 (0.38-0.46)</td><td valign="top" align="center" rowspan="1" colspan="1">1.61</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;1.2 Nodular lymphocyte predominant Hodgkin lymphoma</td><td valign="top" align="center" rowspan="1" colspan="1">9659</td><td valign="top" align="center" rowspan="1" colspan="1">212</td><td valign="top" align="center" rowspan="1" colspan="1">0.54</td><td valign="top" align="center" rowspan="1" colspan="1">38</td><td valign="top" align="center" rowspan="1" colspan="1">0.17 (0.15-0.19)</td><td valign="top" align="center" rowspan="1" colspan="1">0.17 (0.14-0.19)</td><td valign="top" align="center" rowspan="1" colspan="1">2.53</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>Non-Hodgkin lymphoma</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">
<bold>35,489</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>90.64</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>69</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>28.30 (28.01-28.6)</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>31.39 (31.06-31.72)</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>1.21</bold>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>2) Precursor lymphoid neoplasms</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">
<bold>1,574</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>4.02</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>18</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>1.26 (1.19-1.32)</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>1.31 (1.24-1.37)</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>1.48</bold>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;2.1 B-lymphoblastic leukemia/lymphoma</td><td valign="top" align="center" rowspan="1" colspan="1">9728, 9811-9819, 9836</td><td valign="top" align="center" rowspan="1" colspan="1">508</td><td valign="top" align="center" rowspan="1" colspan="1">1.30</td><td valign="top" align="center" rowspan="1" colspan="1">17</td><td valign="top" align="center" rowspan="1" colspan="1">0.41 (0.37-0.44)</td><td valign="top" align="center" rowspan="1" colspan="1">0.42 (0.38-0.46)</td><td valign="top" align="center" rowspan="1" colspan="1">1.07</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;2.2 T-lymphoblastic leukemia/lymphoma</td><td valign="top" align="center" rowspan="1" colspan="1">9729, 9837</td><td valign="top" align="center" rowspan="1" colspan="1">242</td><td valign="top" align="center" rowspan="1" colspan="1">0.62</td><td valign="top" align="center" rowspan="1" colspan="1">21</td><td valign="top" align="center" rowspan="1" colspan="1">0.19 (0.17-0.22)</td><td valign="top" align="center" rowspan="1" colspan="1">0.20 (0.17-0.22)</td><td valign="top" align="center" rowspan="1" colspan="1">3.03</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;2.3 Lymphoblastic leukemia/lymphoma</td><td valign="top" align="center" rowspan="1" colspan="1">9727, 9835</td><td valign="top" align="center" rowspan="1" colspan="1">824</td><td valign="top" align="center" rowspan="1" colspan="1">2.10</td><td valign="top" align="center" rowspan="1" colspan="1">18</td><td valign="top" align="center" rowspan="1" colspan="1">0.66 (0.61-0.7)</td><td valign="top" align="center" rowspan="1" colspan="1">0.69 (0.64-0.74)</td><td valign="top" align="center" rowspan="1" colspan="1">1.50</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>3) Mature B-cell neoplasms</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">
<bold>29,429</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>75.16</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>69</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>23.47 (23.2-23.74)</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>26.17 (25.87-26.47)</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>1.19</bold>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;3.1 Chronic lymphocytic leukemia/small lymphocytic lymphoma</td><td valign="top" align="center" rowspan="1" colspan="1">9670, 9823</td><td valign="top" align="center" rowspan="1" colspan="1">6,167</td><td valign="top" align="center" rowspan="1" colspan="1">15.75</td><td valign="top" align="center" rowspan="1" colspan="1">73</td><td valign="top" align="center" rowspan="1" colspan="1">4.92 (4.8-5.04)</td><td valign="top" align="center" rowspan="1" colspan="1">5.61 (5.47-5.75)</td><td valign="top" align="center" rowspan="1" colspan="1">1.41</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;3.2 B-cell prolymphocytic leukemia</td><td valign="top" align="center" rowspan="1" colspan="1">9833</td><td valign="top" align="center" rowspan="1" colspan="1">29</td><td valign="top" align="center" rowspan="1" colspan="1">0.07</td><td valign="top" align="center" rowspan="1" colspan="1">72</td><td valign="top" align="center" rowspan="1" colspan="1">0.02 (0.01-0.03)</td><td valign="top" align="center" rowspan="1" colspan="1">0.03 (0.02-0.04)</td><td valign="top" align="center" rowspan="1" colspan="1">0.93</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;3.3 Mantle cell lymphoma</td><td valign="top" align="center" rowspan="1" colspan="1">9673</td><td valign="top" align="center" rowspan="1" colspan="1">896</td><td valign="top" align="center" rowspan="1" colspan="1">2.29</td><td valign="top" align="center" rowspan="1" colspan="1">69</td><td valign="top" align="center" rowspan="1" colspan="1">0.71 (0.67-0.76)</td><td valign="top" align="center" rowspan="1" colspan="1">0.81 (0.76-0.87)</td><td valign="top" align="center" rowspan="1" colspan="1">2.28</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;3.4 Lymphoplasmacytic lymphoma/Waldenstr&#246;m&#8217;s Macroglobulinemia</td><td valign="top" align="center" rowspan="1" colspan="1">9671, 9761</td><td valign="top" align="center" rowspan="1" colspan="1">880</td><td valign="top" align="center" rowspan="1" colspan="1">2.25</td><td valign="top" align="center" rowspan="1" colspan="1">72</td><td valign="top" align="center" rowspan="1" colspan="1">0.70 (0.66-0.75)</td><td valign="top" align="center" rowspan="1" colspan="1">0.80 (0.74-0.85)</td><td valign="top" align="center" rowspan="1" colspan="1">1.75</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;3.5 Diffuse large B-cell lymphoma</td><td valign="top" align="center" rowspan="1" colspan="1">9675, 9678-9680, 9684, 9688, 9712, 9735, 9737-9738</td><td valign="top" align="center" rowspan="1" colspan="1">6,933</td><td valign="top" align="center" rowspan="1" colspan="1">17.71</td><td valign="top" align="center" rowspan="1" colspan="1">68</td><td valign="top" align="center" rowspan="1" colspan="1">5.53 (5.4-5.66)</td><td valign="top" align="center" rowspan="1" colspan="1">6.04 (5.9-6.19)</td><td valign="top" align="center" rowspan="1" colspan="1">1.16</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;3.6 Burkitt lymphoma/leukemia</td><td valign="top" align="center" rowspan="1" colspan="1">9687, 9826</td><td valign="top" align="center" rowspan="1" colspan="1">428</td><td valign="top" align="center" rowspan="1" colspan="1">1.09</td><td valign="top" align="center" rowspan="1" colspan="1">38</td><td valign="top" align="center" rowspan="1" colspan="1">0.34 (0.31-0.37)</td><td valign="top" align="center" rowspan="1" colspan="1">0.35 (0.32-0.39)</td><td valign="top" align="center" rowspan="1" colspan="1">2.04</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;3.7 Marginal zone lymphoma</td><td valign="top" align="center" rowspan="1" colspan="1">9689, 9699, 9764</td><td valign="top" align="center" rowspan="1" colspan="1">2,105</td><td valign="top" align="center" rowspan="1" colspan="1">5.38</td><td valign="top" align="center" rowspan="1" colspan="1">65</td><td valign="top" align="center" rowspan="1" colspan="1">1.68 (1.61-1.75)</td><td valign="top" align="center" rowspan="1" colspan="1">1.84 (1.76-1.92)</td><td valign="top" align="center" rowspan="1" colspan="1">1.02</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;3.7.1 Splenic marginal zone lymphoma</td><td valign="top" align="center" rowspan="1" colspan="1">9689</td><td valign="top" align="center" rowspan="1" colspan="1">403</td><td valign="top" align="center" rowspan="1" colspan="1">1.03</td><td valign="top" align="center" rowspan="1" colspan="1">68</td><td valign="top" align="center" rowspan="1" colspan="1">0.32 (0.29-0.35)</td><td valign="top" align="center" rowspan="1" colspan="1">0.36 (0.33-0.4)</td><td valign="top" align="center" rowspan="1" colspan="1">0.91</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;3.7.2 Extranodal marginal zone lymphoma</td><td valign="top" align="center" rowspan="1" colspan="1">9699 (excluding C77.0-C77.9)</td><td valign="top" align="center" rowspan="1" colspan="1">1,421</td><td valign="top" align="center" rowspan="1" colspan="1">3.63</td><td valign="top" align="center" rowspan="1" colspan="1">62</td><td valign="top" align="center" rowspan="1" colspan="1">1.13 (1.07-1.19)</td><td valign="top" align="center" rowspan="1" colspan="1">1.23 (1.16-1.29)</td><td valign="top" align="center" rowspan="1" colspan="1">1.06</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;3.7.3 Nodal marginal zone lymphoma</td><td valign="top" align="center" rowspan="1" colspan="1">9699 (C77.0-C77.9)</td><td valign="top" align="center" rowspan="1" colspan="1">280</td><td valign="top" align="center" rowspan="1" colspan="1">0.72</td><td valign="top" align="center" rowspan="1" colspan="1">66</td><td valign="top" align="center" rowspan="1" colspan="1">0.22 (0.2-0.25)</td><td valign="top" align="center" rowspan="1" colspan="1">0.25 (0.22-0.28)</td><td valign="top" align="center" rowspan="1" colspan="1">0.96</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;3.8 Follicular lymphoma</td><td valign="top" align="center" rowspan="1" colspan="1">9597, 9690, 9691, 9695, 9698</td><td valign="top" align="center" rowspan="1" colspan="1">4,257</td><td valign="top" align="center" rowspan="1" colspan="1">10.87</td><td valign="top" align="center" rowspan="1" colspan="1">62</td><td valign="top" align="center" rowspan="1" colspan="1">3.39 (3.29-3.5)</td><td valign="top" align="center" rowspan="1" colspan="1">3.70 (3.59-3.81)</td><td valign="top" align="center" rowspan="1" colspan="1">0.94</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;3.9 Hairy cell leukemia</td><td valign="top" align="center" rowspan="1" colspan="1">9940</td><td valign="top" align="center" rowspan="1" colspan="1">274</td><td valign="top" align="center" rowspan="1" colspan="1">0.70</td><td valign="top" align="center" rowspan="1" colspan="1">61</td><td valign="top" align="center" rowspan="1" colspan="1">0.22 (0.19-0.24)</td><td valign="top" align="center" rowspan="1" colspan="1">0.24 (0.21-0.26)</td><td valign="top" align="center" rowspan="1" colspan="1">3.35</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;3.10 Plasma cell neoplasms</td><td valign="top" align="center" rowspan="1" colspan="1">9731-9734</td><td valign="top" align="center" rowspan="1" colspan="1">7,444</td><td valign="top" align="center" rowspan="1" colspan="1">19.01</td><td valign="top" align="center" rowspan="1" colspan="1">73</td><td valign="top" align="center" rowspan="1" colspan="1">5.94 (5.8-6.07)</td><td valign="top" align="center" rowspan="1" colspan="1">6.75 (6.59-6.9)</td><td valign="top" align="center" rowspan="1" colspan="1">1.06</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;3.10.1 Solitary plasmocytoma of bone</td><td valign="top" align="center" rowspan="1" colspan="1">9731</td><td valign="top" align="center" rowspan="1" colspan="1">266</td><td valign="top" align="center" rowspan="1" colspan="1">0.68</td><td valign="top" align="center" rowspan="1" colspan="1">66</td><td valign="top" align="center" rowspan="1" colspan="1">0.21 (0.19-0.24)</td><td valign="top" align="center" rowspan="1" colspan="1">0.24 (0.21-0.27)</td><td valign="top" align="center" rowspan="1" colspan="1">1.56</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;3.10.2 Extraosseus plasmocytoma</td><td valign="top" align="center" rowspan="1" colspan="1">9734</td><td valign="top" align="center" rowspan="1" colspan="1">117</td><td valign="top" align="center" rowspan="1" colspan="1">0.30</td><td valign="top" align="center" rowspan="1" colspan="1">68</td><td valign="top" align="center" rowspan="1" colspan="1">0.09 (0.08-0.11)</td><td valign="top" align="center" rowspan="1" colspan="1">0.10 (0.08-0.12)</td><td valign="top" align="center" rowspan="1" colspan="1">1.85</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;3.10.3 Plasma cell myeloma/leukemia</td><td valign="top" align="center" rowspan="1" colspan="1">9732-9733</td><td valign="top" align="center" rowspan="1" colspan="1">7,061</td><td valign="top" align="center" rowspan="1" colspan="1">18.03</td><td valign="top" align="center" rowspan="1" colspan="1">73</td><td valign="top" align="center" rowspan="1" colspan="1">5.63 (5.5-5.76)</td><td valign="top" align="center" rowspan="1" colspan="1">6.41 (6.25-6.56)</td><td valign="top" align="center" rowspan="1" colspan="1">1.04</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;3.11 B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classical HL</td><td valign="top" align="center" rowspan="1" colspan="1">9596</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>16</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>0.04</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>46</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>0.01 (0.01-0.02)</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>0.01 (0.01-0.02)</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>1.00</bold>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>4) Mature-T-cell and NK-cell neoplasms</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">
<bold>2,345</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>5.99</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>62</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>1.87 (1.79-1.95)</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>2.01 (1.93-2.09)</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>1.52</bold>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;4.1 Mycosis fungoides/Sezary syndrome</td><td valign="top" align="center" rowspan="1" colspan="1">9700, 9701</td><td valign="top" align="center" rowspan="1" colspan="1">840</td><td valign="top" align="center" rowspan="1" colspan="1">2.15</td><td valign="top" align="center" rowspan="1" colspan="1">62</td><td valign="top" align="center" rowspan="1" colspan="1">0.67 (0.62-0.72)</td><td valign="top" align="center" rowspan="1" colspan="1">0.72 (0.67-0.77)</td><td valign="top" align="center" rowspan="1" colspan="1">1.51</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;4.2 Peripheral T/NK-cell lymphoma</td><td valign="top" align="center" rowspan="1" colspan="1">9702, 9705, 9708-9709, 9714-9717, 9724-9726</td><td valign="top" align="center" rowspan="1" colspan="1">1,142</td><td valign="top" align="center" rowspan="1" colspan="1">2.92</td><td valign="top" align="center" rowspan="1" colspan="1">63</td><td valign="top" align="center" rowspan="1" colspan="1">0.91 (0.86-0.96)</td><td valign="top" align="center" rowspan="1" colspan="1">0.98 (0.92-1.03)</td><td valign="top" align="center" rowspan="1" colspan="1">1.63</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;4.2.1 Peripheral T-cell lymphoma, NOS</td><td valign="top" align="center" rowspan="1" colspan="1">9702</td><td valign="top" align="center" rowspan="1" colspan="1">492</td><td valign="top" align="center" rowspan="1" colspan="1">1.26</td><td valign="top" align="center" rowspan="1" colspan="1">66</td><td valign="top" align="center" rowspan="1" colspan="1">0.39 (0.36-0.43)</td><td valign="top" align="center" rowspan="1" colspan="1">0.42 (0.39-0.46)</td><td valign="top" align="center" rowspan="1" colspan="1">1.83</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;4.2.2 Angioimmunoblastic T-cell lymphoma</td><td valign="top" align="center" rowspan="1" colspan="1">9705</td><td valign="top" align="center" rowspan="1" colspan="1">177</td><td valign="top" align="center" rowspan="1" colspan="1">0.45</td><td valign="top" align="center" rowspan="1" colspan="1">69</td><td valign="top" align="center" rowspan="1" colspan="1">0.14 (0.12-0.16)</td><td valign="top" align="center" rowspan="1" colspan="1">0.16 (0.13-0.18)</td><td valign="top" align="center" rowspan="1" colspan="1">1.72</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;4.2.3 Subcutaneous panniculitis-like T-cell lymphoma</td><td valign="top" align="center" rowspan="1" colspan="1">9708</td><td valign="top" align="center" rowspan="1" colspan="1">11</td><td valign="top" align="center" rowspan="1" colspan="1">0.03</td><td valign="top" align="center" rowspan="1" colspan="1">69</td><td valign="top" align="center" rowspan="1" colspan="1">0.01 (0-0.01)</td><td valign="top" align="center" rowspan="1" colspan="1">0.01 (0-0.01)</td><td valign="top" align="center" rowspan="1" colspan="1">1.20</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;4.2.4 Anaplastic large cell lymphoma, ALK-positive</td><td valign="top" align="center" rowspan="1" colspan="1">9714</td><td valign="top" align="center" rowspan="1" colspan="1">195</td><td valign="top" align="center" rowspan="1" colspan="1">0.50</td><td valign="top" align="center" rowspan="1" colspan="1">51</td><td valign="top" align="center" rowspan="1" colspan="1">0.16 (0.13-0.18)</td><td valign="top" align="center" rowspan="1" colspan="1">0.16 (0.14-0.18)</td><td valign="top" align="center" rowspan="1" colspan="1">1.91</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;4.2.5 Hepatosplenic T-cell lymphoma</td><td valign="top" align="center" rowspan="1" colspan="1">9716</td><td valign="top" align="center" rowspan="1" colspan="1">11</td><td valign="top" align="center" rowspan="1" colspan="1">0.03</td><td valign="top" align="center" rowspan="1" colspan="1">46</td><td valign="top" align="center" rowspan="1" colspan="1">0.01 (0-0.01)</td><td valign="top" align="center" rowspan="1" colspan="1">0.01 (0-0.01)</td><td valign="top" align="center" rowspan="1" colspan="1">1.20</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;4.2.6 Enteropathy-associated T-cell lymphoma</td><td valign="top" align="center" rowspan="1" colspan="1">9717</td><td valign="top" align="center" rowspan="1" colspan="1">39</td><td valign="top" align="center" rowspan="1" colspan="1">0.10</td><td valign="top" align="center" rowspan="1" colspan="1">56</td><td valign="top" align="center" rowspan="1" colspan="1">0.03 (0.02-0.04)</td><td valign="top" align="center" rowspan="1" colspan="1">0.03 (0.02-0.04)</td><td valign="top" align="center" rowspan="1" colspan="1">1.79</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;4.2.7 Primary cutaneous gamma-delta T-cell lymphoma</td><td valign="top" align="center" rowspan="1" colspan="1">9726</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">0.00</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">0.00 (0&#8211;0)</td><td valign="top" align="center" rowspan="1" colspan="1">0.00 (0&#8211;0)</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;4.2.8 Primary cutaneous T-cell lymphoma, NOS</td><td valign="top" align="center" rowspan="1" colspan="1">9709</td><td valign="top" align="center" rowspan="1" colspan="1">217</td><td valign="top" align="center" rowspan="1" colspan="1">0.55</td><td valign="top" align="center" rowspan="1" colspan="1">61</td><td valign="top" align="center" rowspan="1" colspan="1">0.17 (0.15-0.2)</td><td valign="top" align="center" rowspan="1" colspan="1">0.19 (0.16-0.21)</td><td valign="top" align="center" rowspan="1" colspan="1">1.09</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;4.2.9 Systemic EBV-positive T-cell lymphoproliferative disease of childhood</td><td valign="top" align="center" rowspan="1" colspan="1">9724</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">0.00</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">0.00 (0&#8211;0)</td><td valign="top" align="center" rowspan="1" colspan="1">0.00 (0&#8211;0)</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;4.2.10 Hydroa vacciniforme-like lymphoma</td><td valign="top" align="center" rowspan="1" colspan="1">9725</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">0.00</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">0.00 (0&#8211;0)</td><td valign="top" align="center" rowspan="1" colspan="1">0.00 (00)</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;4.3 Adult T-cell leukemia/lymphoma</td><td valign="top" align="center" rowspan="1" colspan="1">9827</td><td valign="top" align="center" rowspan="1" colspan="1">15</td><td valign="top" align="center" rowspan="1" colspan="1">0.04</td><td valign="top" align="center" rowspan="1" colspan="1">76</td><td valign="top" align="center" rowspan="1" colspan="1">0.01 (0.01-0.02)</td><td valign="top" align="center" rowspan="1" colspan="1">0.01 (0.01-0.02)</td><td valign="top" align="center" rowspan="1" colspan="1">0.88</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;4.4 Extranodal NK/Tcell lymphoma, nasal type</td><td valign="top" align="center" rowspan="1" colspan="1">9719</td><td valign="top" align="center" rowspan="1" colspan="1">80</td><td valign="top" align="center" rowspan="1" colspan="1">0.20</td><td valign="top" align="center" rowspan="1" colspan="1">60</td><td valign="top" align="center" rowspan="1" colspan="1">0.06 (0.05-0.08)</td><td valign="top" align="center" rowspan="1" colspan="1">0.07 (0.05-0.08)</td><td valign="top" align="center" rowspan="1" colspan="1">2.08</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;4.5 T-cell large granular lymphocytic leukemia</td><td valign="top" align="center" rowspan="1" colspan="1">9831</td><td valign="top" align="center" rowspan="1" colspan="1">61</td><td valign="top" align="center" rowspan="1" colspan="1">0.16</td><td valign="top" align="center" rowspan="1" colspan="1">73</td><td valign="top" align="center" rowspan="1" colspan="1">0.05 (0.04-0.06)</td><td valign="top" align="center" rowspan="1" colspan="1">0.05 (0.04-0.07)</td><td valign="top" align="center" rowspan="1" colspan="1">1.35</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;4.6 T-cell prolymphocytic leukemia</td><td valign="top" align="center" rowspan="1" colspan="1">9834</td><td valign="top" align="center" rowspan="1" colspan="1">33</td><td valign="top" align="center" rowspan="1" colspan="1">0.08</td><td valign="top" align="center" rowspan="1" colspan="1">64</td><td valign="top" align="center" rowspan="1" colspan="1">0.03 (0.02-0.04)</td><td valign="top" align="center" rowspan="1" colspan="1">0.03 (0.02-0.04)</td><td valign="top" align="center" rowspan="1" colspan="1">0.94</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;4.7 Aggressive NK cell leukemia</td><td valign="top" align="center" rowspan="1" colspan="1">9948</td><td valign="top" align="center" rowspan="1" colspan="1">9</td><td valign="top" align="center" rowspan="1" colspan="1">0.02</td><td valign="top" align="center" rowspan="1" colspan="1">67</td><td valign="top" align="center" rowspan="1" colspan="1">0.01 (0-0.01)</td><td valign="top" align="center" rowspan="1" colspan="1">0.01 (0-0.01)</td><td valign="top" align="center" rowspan="1" colspan="1">0.80</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;4.8 Primary cutaneous CD30 + T-cell lymphoproliferative disorders</td><td valign="top" align="center" rowspan="1" colspan="1">9718</td><td valign="top" align="center" rowspan="1" colspan="1">165</td><td valign="top" align="center" rowspan="1" colspan="1">0.42</td><td valign="top" align="center" rowspan="1" colspan="1">56</td><td valign="top" align="center" rowspan="1" colspan="1">0.13 (0.11-0.15)</td><td valign="top" align="center" rowspan="1" colspan="1">0.14 (0.12-0.16)</td><td valign="top" align="center" rowspan="1" colspan="1">1.09</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>5) Lymphoid neoplasms, NOS</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>9590, 9591, 9820, 9832, 9970, 9971, 9760, 9762</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>2,141</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>5.47</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>75</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>1.71 (1.64-1.78)</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>1.90 (1.82-1.98)</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>0.99</bold>
</td></tr></tbody></table><table-wrap-foot><p>Bold values highlight the main subtypes and its data.</p></table-wrap-foot></table-wrap></sec><sec id="s2_3"><title>Statistical analysis</title><p>Crude (CR) and age-standardized incidence rates using the 2013 European standard population (ASIRe), were calculated using population data provided by the National Statistics Institute (Instituto Nacional de Estad&#237;stica&#8212;INE) (<xref rid="B18" ref-type="bibr">18</xref>) and expressed per 100,000 inhabitant-years. Poisson regression models were used to analyze trends in incidence rates and estimate the annual percentage change (APC) for each subtype of LN. Specific rates by age for the year 2023 were estimated by applying the APCs for the period 2002&#8211;2013. The projection of the number of cases of LNs for 2023 was determined by applying to the Spanish population of 2023 the age-specific rates estimated for that same year, assuming a stable incidence trend over time.</p><p>For the survival analysis, cases, excluding DCO cases or those diagnosed by autopsy, were followed up until 31 December 2015. Vital status follow-up was carried out using multiple sources of information, such as regional mortality registries, National Death Index, social security database, hospital and primary care records and population censuses, as needed and available in each registry. Observed survival (OS) was estimated by the Kaplan-Meier method and net survival (NS) by the Pohar-Perme estimator (<xref rid="B20" ref-type="bibr">20</xref>). The 1-, 3- and 5-year OS and NS and their corresponding 95% confidence interval (CI) are presented for all LNs as a whole and for their subtypes. Survival between groups of age, sex and period of diagnosis was compared using a log-rank type test (<xref rid="B21" ref-type="bibr">21</xref>). All analyses were performed using R software (version 3.6.1).</p></sec><sec id="s2_4"><title>Ethics approval</title><p>This study has been carried out using anonymized data from the participating PBCRs that comprise REDECAN. For their part, the cancer registries comply with the legal regulations in force in Europe and Spain on the Protection of Personal Data. No intervention has been performed in human or animal subjects. Informed consent of the patients is not required for this type of study.</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><sec id="s3_1"><title>Incidence</title><p>LNs accounted for 69.0% (n=39,156) of all hematological malignancies (n=56,751) diagnosed in the Spanish population covered by the REDECAN during 2002-2013. Among them, 3,667 (9.37%) were Hodgkin lymphoma, 1,574 (4.02%) precursor lymphoid neoplasms, 29,429 (75.16%) mature B-cell neoplasms, 2,345 (5.99%) mature T-cell and NK-cell neoplasms, and 2,141 (5.47%) lymphoid neoplasms, NOS. <xref rid="T1" ref-type="table">
<bold>Table&#160;1</bold>
</xref> lists the number of cases, the percentage over the total of LNs, the median age, the CR and the ASIRe with its 95% CI and sex ratio (male/female) of each subgroup and subtype according to the ICD-O-3 codes. Incidence rates (CR and ASIRe) by sex are shown in <xref rid="SM1" ref-type="supplementary-material">
<bold>Table S2</bold>
</xref> of <xref rid="SM1" ref-type="supplementary-material">
<bold>Supplementary material</bold>
</xref>.</p><p>The ASIRe was 2.84 (95% CI: 2.74, 2.93) for Hodgkin lymphoma, 1.31 (95% CI: 1.24, 1.37) for precursor lymphoid neoplasms, 26.17 (95% CI: 25.87, 26.47) for mature B-cell neoplasms, 2.01 (95% CI: 1.93, 2.09) for mature T-cell and NK-cell neoplasms, and 1.90 (95% CI: 1.82, 1.98) for NOS cases. Median age at diagnosis was 67 years (IQR: 52-77) and there was a marked male predominance: the incidence sex ratio was 1.22 and ranged from 0.91 for splenic marginal zone lymphoma and 0.94 for follicular lymphoma leukemia to 3.03 for T-lymphoblastic leukemia/lymphoma and 3.35 for hairy cell. In both sexes as a whole, the most frequent entities were plasma cell myeloma/leukemia (n=7,061, 18.03%), diffuse large B-cell lymphoma (n=6,933, 17.71%), chronic lymphocytic leukemia/small lymphocytic lymphoma (n=6,167, 15.75%), follicular lymphoma (n=4,257, 10.87%) and classical Hodgkin lymphoma (n=3,455, 8.82%).</p><p>Incidence trends of LNs during 2002-2013 are detailed in <xref rid="T2" ref-type="table">
<bold>Table&#160;2</bold>
</xref>. The incidence of the LN pool was relatively stable over time (APC: 0.3; 95% CI: -0.1, 0.6), while the main subgroups, with the exception of mature T-cell and NK-cell neoplasms, showed significant variations. Within Hodgkin lymphoma, there was a marked increase of nodular lymphocyte predominant subtype (APC: 6.9%). Incidence of precursor neoplasms decreased slightly, yet within this subgroup, there was a marked increase of B- and T- subtypes to the detriment of NOS cases. Among B-mature cell neoplasms, we evidenced a positive trend of follicular lymphoma (4.0%), marginal zone lymphoma (2.9%), and diffuse large B-cell lymphoma (1.2%), in contrast with the negative trend for chronic lymphocytic leukemia/small lymphocytic lymphoma (-2.2%). Among mature T- and NK-cell neoplasms, there was a positive trend for the subgroup that includes peripheral subtypes other than mycosis fungoides/S&#233;zary syndrome. Finally, the NOS subtype decreased markedly (-5.6%). <xref rid="SM1" ref-type="supplementary-material">
<bold>Table S3</bold>
</xref> of <xref rid="SM1" ref-type="supplementary-material">
<bold>Supplementary material</bold>
</xref> displays incidence trends stratified by sex, showing no notable differences between sexes.</p><table-wrap position="float" id="T2" orientation="portrait"><label>Table&#160;2</label><caption><p>Incidence trends of lymphoid neoplasms diagnosed in Spain, 2002-2013.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Subtype</th><th valign="top" align="center" rowspan="1" colspan="1">APC (%)</th><th valign="top" align="center" rowspan="1" colspan="1">95% CI</th><th valign="top" align="center" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>Lymphoid neoplasm, total</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">0.3</td><td valign="top" align="center" rowspan="1" colspan="1">(-0.1, 0.6)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>1) Hodgkin lymphoma</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">1.1</td><td valign="top" align="center" rowspan="1" colspan="1">(0.1, 2.1)</td><td valign="top" align="center" rowspan="1" colspan="1">*</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;1.1 Classical Hodgkin lymphoma</td><td valign="top" align="center" rowspan="1" colspan="1">0,7</td><td valign="top" align="center" rowspan="1" colspan="1">(-0.3, 1.8)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;1.2 Hodgkin lymphoma, nodular lymphocyte predominant</td><td valign="top" align="center" rowspan="1" colspan="1">6.9</td><td valign="top" align="center" rowspan="1" colspan="1">(2.5, 11.5)</td><td valign="top" align="center" rowspan="1" colspan="1">*</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>Non-Hodgkin lymphoma</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">0.2</td><td valign="top" align="center" rowspan="1" colspan="1">(-0.2, 0.5)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>2) Precursor lymphoid neoplasms</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>-2,0</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>(-3.5, -0.5)</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>*</bold>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;2.1 B-lymphoblastic leukemia/lymphoma</td><td valign="top" align="center" rowspan="1" colspan="1">4,0</td><td valign="top" align="center" rowspan="1" colspan="1">(1.2, 6.8)</td><td valign="top" align="center" rowspan="1" colspan="1">*</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;2.2 T-lymphoblastic leukemia/lymphoma</td><td valign="top" align="center" rowspan="1" colspan="1">5.2</td><td valign="top" align="center" rowspan="1" colspan="1">(1.2, 9.4)</td><td valign="top" align="center" rowspan="1" colspan="1">*</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;2.3 Lymphoblastic leukemia/lymphoma</td><td valign="top" align="center" rowspan="1" colspan="1">-7,5</td><td valign="top" align="center" rowspan="1" colspan="1">(-9.4, -5.5)</td><td valign="top" align="center" rowspan="1" colspan="1">*</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>3) Mature B-cell neoplasms</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">0.6</td><td valign="top" align="center" rowspan="1" colspan="1">(0.3, 1.0)</td><td valign="top" align="center" rowspan="1" colspan="1">*</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;3.1 Chronic lymphocytic leukemia/small lymphocytic lymphoma</td><td valign="top" align="center" rowspan="1" colspan="1">-2,2</td><td valign="top" align="center" rowspan="1" colspan="1">(-3.0, -1.5)</td><td valign="top" align="center" rowspan="1" colspan="1">*</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;3.2 B-cell prolymphocytic leukemia</td><td valign="top" align="center" rowspan="1" colspan="1">5.7</td><td valign="top" align="center" rowspan="1" colspan="1">(-5.6, 18.4)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;3.3 Hairy cell leukemia</td><td valign="top" align="center" rowspan="1" colspan="1">-0,8</td><td valign="top" align="center" rowspan="1" colspan="1">(-4.4, 2.9)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;3.4 Marginal zone lymphoma</td><td valign="top" align="center" rowspan="1" colspan="1">2,9</td><td valign="top" align="center" rowspan="1" colspan="1">(1.5, 4.2)</td><td valign="top" align="center" rowspan="1" colspan="1">*</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;3.5 Lymphoplasmacytic lymphoma/Waldenstr&#246;m&#8217;s macroglobulinemia</td><td valign="top" align="center" rowspan="1" colspan="1">1.0</td><td valign="top" align="center" rowspan="1" colspan="1">(-1.0, 3.1)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;3.6 Plasma cell myeloma/leukemia</td><td valign="top" align="center" rowspan="1" colspan="1">0.1</td><td valign="top" align="center" rowspan="1" colspan="1">(-0.6, 0.8)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;3.7 Follicular lymphoma</td><td valign="top" align="center" rowspan="1" colspan="1">4.0</td><td valign="top" align="center" rowspan="1" colspan="1">(3.1, 5.0)</td><td valign="top" align="center" rowspan="1" colspan="1">*</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;3.8 Mantle cell lymphoma</td><td valign="top" align="center" rowspan="1" colspan="1">-0,7</td><td valign="top" align="center" rowspan="1" colspan="1">(-2.7, 1.3)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;3.9 Diffuse large B-cell lymphoma</td><td valign="top" align="center" rowspan="1" colspan="1">1.2</td><td valign="top" align="center" rowspan="1" colspan="1">(0.5, 2.0)</td><td valign="top" align="center" rowspan="1" colspan="1">*</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;3.10 Burkitt lymphoma/leukemia</td><td valign="top" align="center" rowspan="1" colspan="1">-0,8</td><td valign="top" align="center" rowspan="1" colspan="1">(-3.7, 2.1)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;3.11 Composite Hodgkin and non-Hodgkin lymphoma</td><td valign="top" align="center" rowspan="1" colspan="1">44.3</td><td valign="top" align="center" rowspan="1" colspan="1">(17.6, 77.1)</td><td valign="top" align="center" rowspan="1" colspan="1">*</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>4) Mature-T-cell and NK-cell neoplasms</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>1.3</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>(0.0, 2.6)</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;4.1 Mycosis fungoides/S&#233;zary syndrome</td><td valign="top" align="center" rowspan="1" colspan="1">-0,4</td><td valign="top" align="center" rowspan="1" colspan="1">(-2.5, 1.7)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;4.2 Other peripheral T- cell and NK-cell lymphoma</td><td valign="top" align="center" rowspan="1" colspan="1">2,3</td><td valign="top" align="center" rowspan="1" colspan="1">(0.7, 3.9)</td><td valign="top" align="center" rowspan="1" colspan="1">*</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>5) Lymphoid neoplasms, NOS</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>-5,6</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>(-6.8, -4.3)</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>*</bold>
</td></tr></tbody></table><table-wrap-foot><p>Bold values highlight the main subtypes and its data.</p><p>* p-value &lt; 0.05.</p></table-wrap-foot></table-wrap></sec><sec id="s3_2"><title>Projections for 2023</title><p>Predicted incidence rates of LNs subtypes for 2023, overall and by sex, are detailed in <xref rid="SM1" ref-type="supplementary-material">
<bold>Table S4</bold>
</xref> of <xref rid="SM1" ref-type="supplementary-material">
<bold>Supplementary material</bold>
</xref>. According to our predictions, 17,926 new cases of LNs will be diagnosed in Spain in 2023, of which 1,513 will be Hodgkin lymphoma, 446 precursor lymphoid neoplasms, 14,211 mature B-cell neoplasms, 1,133 mature T-cell and NK-cell neoplasms and 624 lymphoid neoplasms NOS.</p></sec><sec id="s3_3"><title>Survival</title><p>A total of 38,699 LNs were included in the survival analysis. <xref rid="T3" ref-type="table">
<bold>Table&#160;3</bold>
</xref> shows a simplified classification of LNs subtypes with its number of cases, 5-year OS and NS with their 95% CI. A more extensive table that also includes 1- and 3 -year OS and NS is available in <xref rid="SM1" ref-type="supplementary-material">
<bold>Supplementary material</bold>
</xref>, <xref rid="SM1" ref-type="supplementary-material">
<bold>Table S5</bold>
</xref>. The overall 5-y OS and NS were 56.84% (95% CI: 56.33-57.34) and 62.81% (95% CI: 62.1-63.52), respectively. Within the major categories, Hodgkin lymphoma showed higher 5-y NS (82.6%, 95% CI: 81.25-83.98) compared to non-Hodgkin lymphoma 5-y NS (60.74%, 95% CI: 59.97-61.51), with the rates being higher in mature T-cell and NK-cell neoplasms (64.19%, 95% CI: 61.78-66.7) and mature B-cell neoplasms (62.11%, 95% CI: 61.25-62.99) than in precursor lymphoid neoplasms (54.33%, 95% CI: 51.75-57.03). Regarding specific lymphoma subtypes, the lowest survival rates were observed in plasma cell myeloma/leukemia (39.21%, 95% CI: 37.87-40.61), B-cell prolymphocytic leukemia (47.27%, 95% CI: 29.5-75.74), peripheral T- cell and NK-cell lymphoma (52.12%, 95% CI: 49.18-55.22) and mantle cell lymphoma (52.42%, 95% CI: 48.64-56.51). By contrast, the highest survival rates were estimated for Hodgkin lymphoma nodular lymphocyte predominant (90.25%, 95% CI: 85.79-94.93), hairy cell leukemia (85.89%, 95% CI: 79.87-92.37) and mycosis fungoides/S&#233;zary syndrome (85.76%, 95% CI: 82.02-89.66).</p><table-wrap position="float" id="T3" orientation="portrait"><label>Table&#160;3</label><caption><p>Five-years observed and net survival of lymphoid neoplasms in Spain.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Subtypes</th><th valign="top" align="center" rowspan="1" colspan="1">N</th><th valign="top" align="center" rowspan="1" colspan="1">5-year observed survival (%)</th><th valign="top" align="center" rowspan="1" colspan="1">95% CI</th><th valign="top" align="center" rowspan="1" colspan="1">5-year net survival (%)</th><th valign="top" align="center" rowspan="1" colspan="1">95% CI</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>Lymphoid neoplasm, total</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>38,699</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>56.84</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>(56.33-57.34)</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>62.81</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>(62.1-63.52)</bold>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>1) Hodgkin lymphoma</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>3,651</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>80.72</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>(79.43-82.04)</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>82.6</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>(81.25-83.98)</bold>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;1.1 Classical Hodgkin lymphoma</td><td valign="top" align="center" rowspan="1" colspan="1">3,439</td><td valign="top" align="center" rowspan="1" colspan="1">80.22</td><td valign="top" align="center" rowspan="1" colspan="1">(78.87-81.58)</td><td valign="top" align="center" rowspan="1" colspan="1">82.13</td><td valign="top" align="center" rowspan="1" colspan="1">(80.72-83.56)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;1.2 Hodgkin lymphoma, nodular lymphocyte predominant</td><td valign="top" align="center" rowspan="1" colspan="1">212</td><td valign="top" align="center" rowspan="1" colspan="1">88.96</td><td valign="top" align="center" rowspan="1" colspan="1">(84.68-93.45)</td><td valign="top" align="center" rowspan="1" colspan="1">90.25</td><td valign="top" align="center" rowspan="1" colspan="1">(85.79-94.93)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>Non-Hodgkin lymphoma</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>35,048</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>54.34</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>(53.8-54.88)</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>60.74</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>(59.97-61.51)</bold>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>2) Precursor lymphoid neoplasms</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>1,464</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>53.8</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>(51.27-56.46)</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>54.33</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>(51.75-57.03)</bold>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;2.1 B-lymphoblastic leukemia/lymphoma</td><td valign="top" align="center" rowspan="1" colspan="1">474</td><td valign="top" align="center" rowspan="1" colspan="1">55.15</td><td valign="top" align="center" rowspan="1" colspan="1">(50.78-59.9)</td><td valign="top" align="center" rowspan="1" colspan="1">55.59</td><td valign="top" align="center" rowspan="1" colspan="1">(51.17-60.4)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;2.2 T-lymphoblastic leukemia/lymphoma</td><td valign="top" align="center" rowspan="1" colspan="1">235</td><td valign="top" align="center" rowspan="1" colspan="1">52.71</td><td valign="top" align="center" rowspan="1" colspan="1">(46.59-59.63)</td><td valign="top" align="center" rowspan="1" colspan="1">53.13</td><td valign="top" align="center" rowspan="1" colspan="1">(46.95-60.13)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;2.3 Lymphoblastic leukemia/lymphoma</td><td valign="top" align="center" rowspan="1" colspan="1">755</td><td valign="top" align="center" rowspan="1" colspan="1">53.33</td><td valign="top" align="center" rowspan="1" colspan="1">(49.85-57.06)</td><td valign="top" align="center" rowspan="1" colspan="1">53.92</td><td valign="top" align="center" rowspan="1" colspan="1">(50.36-57.73)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>3) Mature B-cell neoplasms</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>29,236</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>55.38</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>(54.8-55.97)</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>62.11</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>(61.25-62.99)</bold>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">3.1 Chronic lymphocytic leukemia/small lymphocytic lymphoma</td><td valign="top" align="center" rowspan="1" colspan="1">6,136</td><td valign="top" align="center" rowspan="1" colspan="1">62.67</td><td valign="top" align="center" rowspan="1" colspan="1">(61.44-63.93)</td><td valign="top" align="center" rowspan="1" colspan="1">74.54</td><td valign="top" align="center" rowspan="1" colspan="1">(71.86-77.32)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;3.2 B-cell prolymphocytic leukemia</td><td valign="top" align="center" rowspan="1" colspan="1">29</td><td valign="top" align="center" rowspan="1" colspan="1">43.47</td><td valign="top" align="center" rowspan="1" colspan="1">(28.37-66.59)</td><td valign="top" align="center" rowspan="1" colspan="1">47.27</td><td valign="top" align="center" rowspan="1" colspan="1">(29.5-75.74)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;3.3 Hairy cell leukemia</td><td valign="top" align="center" rowspan="1" colspan="1">273</td><td valign="top" align="center" rowspan="1" colspan="1">77.75</td><td valign="top" align="center" rowspan="1" colspan="1">(72.83-83.01)</td><td valign="top" align="center" rowspan="1" colspan="1">85.89</td><td valign="top" align="center" rowspan="1" colspan="1">(79.87-92.37)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;3.4 Marginal zone lymphoma</td><td valign="top" align="center" rowspan="1" colspan="1">2,102</td><td valign="top" align="center" rowspan="1" colspan="1">76.4</td><td valign="top" align="center" rowspan="1" colspan="1">(74.55-78.3)</td><td valign="top" align="center" rowspan="1" colspan="1">83.62</td><td valign="top" align="center" rowspan="1" colspan="1">(81.16-86.15)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;3.5 Lymphoplasmacytic lymphoma/Waldenstr&#246;m&#8217;s macroglobulinemia</td><td valign="top" align="center" rowspan="1" colspan="1">864</td><td valign="top" align="center" rowspan="1" colspan="1">60.88</td><td valign="top" align="center" rowspan="1" colspan="1">(57.57-64.38)</td><td valign="top" align="center" rowspan="1" colspan="1">69.8</td><td valign="top" align="center" rowspan="1" colspan="1">(65.45-74.44)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;3.6 Plasma cell myeloma/leukemia</td><td valign="top" align="center" rowspan="1" colspan="1">7,324</td><td valign="top" align="center" rowspan="1" colspan="1">34.71</td><td valign="top" align="center" rowspan="1" colspan="1">(33.59-35.86)</td><td valign="top" align="center" rowspan="1" colspan="1">39.21</td><td valign="top" align="center" rowspan="1" colspan="1">(37.87-40.61)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;3.7 Follicular lymphoma</td><td valign="top" align="center" rowspan="1" colspan="1">4,249</td><td valign="top" align="center" rowspan="1" colspan="1">77.58</td><td valign="top" align="center" rowspan="1" colspan="1">(76.29-78.89)</td><td valign="top" align="center" rowspan="1" colspan="1">83.29</td><td valign="top" align="center" rowspan="1" colspan="1">(81.78-84.83)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;3.8 Mantle cell lymphoma</td><td valign="top" align="center" rowspan="1" colspan="1">896</td><td valign="top" align="center" rowspan="1" colspan="1">46.81</td><td valign="top" align="center" rowspan="1" colspan="1">(43.56-50.3)</td><td valign="top" align="center" rowspan="1" colspan="1">52.42</td><td valign="top" align="center" rowspan="1" colspan="1">(48.64-56.51)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;3.9 Diffuse large B-cell lymphoma</td><td valign="top" align="center" rowspan="1" colspan="1">6,930</td><td valign="top" align="center" rowspan="1" colspan="1">50.48</td><td valign="top" align="center" rowspan="1" colspan="1">(49.29-51.69)</td><td valign="top" align="center" rowspan="1" colspan="1">55.58</td><td valign="top" align="center" rowspan="1" colspan="1">(54.2-57)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;3.10 Burkitt lymphoma/leukemia</td><td valign="top" align="center" rowspan="1" colspan="1">417</td><td valign="top" align="center" rowspan="1" colspan="1">55.92</td><td valign="top" align="center" rowspan="1" colspan="1">(51.33-60.92)</td><td valign="top" align="center" rowspan="1" colspan="1">56.91</td><td valign="top" align="center" rowspan="1" colspan="1">(52.23-62.01)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;3.11 Composite Hodgkin and non-Hodgkin lymphoma</td><td valign="top" align="center" rowspan="1" colspan="1">16</td><td valign="top" align="center" rowspan="1" colspan="1">81.25</td><td valign="top" align="center" rowspan="1" colspan="1">(64.21-100)</td><td valign="top" align="center" rowspan="1" colspan="1">83.35</td><td valign="top" align="center" rowspan="1" colspan="1">(66.09-105.13)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>4) Mature-T-cell and NK-cell neoplasms</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>2,342</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>58.76</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>(56.77-60.83)</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>64.19</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>(61.78-66.7)</bold>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;4.1 Mycosis fungoides/S&#233;zary syndrome</td><td valign="top" align="center" rowspan="1" colspan="1">838</td><td valign="top" align="center" rowspan="1" colspan="1">78.36</td><td valign="top" align="center" rowspan="1" colspan="1">(75.53-81.28)</td><td valign="top" align="center" rowspan="1" colspan="1">85.76</td><td valign="top" align="center" rowspan="1" colspan="1">(82.02-89.66)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;4.2 Other peripheral T- cell and NK-cell lymphoma</td><td valign="top" align="center" rowspan="1" colspan="1">1,504</td><td valign="top" align="center" rowspan="1" colspan="1">47.84</td><td valign="top" align="center" rowspan="1" colspan="1">(45.34-50.48)</td><td valign="top" align="center" rowspan="1" colspan="1">52.12</td><td valign="top" align="center" rowspan="1" colspan="1">(49.18-55.22)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>5) Lymphoid neoplasms, NOS</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>2,006</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>34.3</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>(32.25-36.47)</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>41.07</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>(38.43-43.9)</bold>
</td></tr></tbody></table><table-wrap-foot><p>Bold values highlight the main subtypes and its data.</p></table-wrap-foot></table-wrap><p>Changes in 5-y NS according to sex, age-group and period of diagnosis (i.e. 2002-2007 and 2008-2013) are displayed in <xref rid="f1" ref-type="fig">
<bold>Figures&#160;1&#8211;3</bold>
</xref>, respectively; specific survival values and p-values for log-rank type test are listed in <xref rid="SM1" ref-type="supplementary-material">
<bold>Tables S6&#8211;S8</bold>
</xref> of <xref rid="SM1" ref-type="supplementary-material">
<bold>Supplementary material</bold>
</xref>. Extended versions of these figures for mature T-cell and NK-cell neoplasms subtypes are displayed in <xref rid="SM1" ref-type="supplementary-material">
<bold>Figures S1&#8211;S3</bold>
</xref> of <xref rid="SM1" ref-type="supplementary-material">
<bold>Supplementary material</bold>
</xref>. Slight but statistically significant differences in 5-y NS between sexes were reported globally (<xref rid="f1" ref-type="fig">
<bold>Figure&#160;1</bold>
</xref>), mostly due to changes in mature B-cell [62.67% (95% CI: 61.21-64.17) for women and 61.65% (95% CI: 60.65-62.66) for men; p-value for log-rank type test &lt;0.001] and mature T/NK-cell neoplasms [67.91% (95% CI: 64.18-71.87) for women and 61.73% (95% CI: 58.63-65) for men; p-value for log-rank type test &lt;0.001]. By contrast, marked differences were found across age-groups (<xref rid="f2" ref-type="fig">
<bold>Figure&#160;2</bold>
</xref>) and between both periods of diagnosis (<xref rid="f3" ref-type="fig">
<bold>Figure&#160;3</bold>
</xref>). Five-y NS of all LNs decreased gradually across age-groups, being 86.69% (95% CI: 84.41-89.03) in children (&lt;15 years), 81.4% (95% CI: 80.5-82.3) in 15-49 years, 71.4% (95% CI: 70.54-72.27) in 50-69 years, and 46.83% (95% CI: 45.53-48.17) in those aged 70+ years (p-value for log-rank type test &lt;0.001). This pattern was reported for all LNs subgroups. Regarding the period of diagnosis, we reported an increase of LNs global survival in the second period 2008-2013 (5-y NS: 64.17%; 95% IC: 63.29-65.07) compared to the period 2002-2007 (5-y NS: 61.57%; 95% CI: 60.56-62.61). This was mostly attributed to an improvement of mature B-cell neoplasms survival (p-value for log-rank type test &lt;0.001), more specifically plasma cell neoplasms (p-value for log-rank type test &lt;0.001) and mantle cell lymphoma (p-value for log-rank type test = 0.005).</p><fig position="float" id="f1" orientation="portrait"><label>Figure&#160;1</label><caption><p>Estimates of 5-year net survival for patients with lymphoid neoplasms diagnosed in 2002-2013, in Spain, according to sex. LN, Lymphoid neoplasm; HL, Hodgkin lymphoma; PLN, precursor lymphoid neoplasms; mature B, mature B-cell neoplasms; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; MZL, marginal zone lymphoma; LL/WM, lymphoplasmacytic lymphoma/Waldenstr&#246;m&#8217;s macroglobulinemia; PCN, plasma cell neoplasms; FL, follicular lymphoma; MCL, mantle cell lymphoma; DLBCL, diffuse large B-cell lymphoma; Burkitt, Burkitt lymphoma/leukemia; Mature T/NK, mature T-cell and NK-cell neoplasms; NOS, not otherwise specified.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fonc-12-1046307-g001.jpg"/></fig><fig position="float" id="f2" orientation="portrait"><label>Figure&#160;2</label><caption><p>Estimates of 5-year net survival for patients with lymphoid neoplasms diagnosed in 2002-2013, in Spain, according to age-group (0-14, 15-49, 50-69 and 70 or more). LN, Lymphoid neoplasm; HL, Hodgkin lymphoma; PLN, precursor lymphoid neoplasms; mature B, mature B-cell neoplasms; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; MZL, marginal zone lymphoma; LL/WM, lymphoplasmacytic lymphoma/Waldenstr&#246;m&#8217;s macroglobulinemia; PCN, plasma cell neoplasms; FL, follicular lymphoma; MCL, mantle cell lymphoma; DLBCL, diffuse large B-cell lymphoma; Burkitt, Burkitt lymphoma/leukemia; Mature T/NK, mature T-cell and NK-celll neoplasms; NOS, not otherwise specified.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fonc-12-1046307-g002.jpg"/></fig><fig position="float" id="f3" orientation="portrait"><label>Figure&#160;3</label><caption><p>Estimates of 5-year net survival for patients with lymphoid neoplasms diagnosed in 2002-2013, in Spain, according to period of diagnosis (2002-2007 and 2008-2013). LN, Lymphoid neoplasm; HL, Hodgkin lymphoma; PLN, precursor lymphoid neoplasms; mature B, mature B-cell neoplasms; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; MZL, marginal zone lymphoma; LL/WM, lymphoplasmacytic lymphoma/Waldenstr&#246;m&#8217;s macroglobulinemia; PCN, plasma cell neoplasms; FL, follicular lymphoma; MCL, mantle cell lymphoma; DLBCL, diffuse large B-cell lymphoma; Burkitt, Burkitt lymphoma/leukemia; Mature T/NK, mature T-cell and NK-celll neoplasms; NOS, not otherwise specified.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fonc-12-1046307-g003.jpg"/></fig></sec></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>This paper presents population-based incidence and survival of LNs in Spain during the period 2002-2013. Our study, which includes 39,156 cases diagnosed and registered by the 13 Spanish PBCRs that make up REDECAN, further complements existing European data by providing incidence patterns, projections for 2023 and survival analysis of LNs by subtypes.</p><p>Incidence rates for the most frequent subtypes are in line with those reported in large European datasets (<xref rid="B10" ref-type="bibr">10</xref>), as well as by hematology-specialized registries from the United Kingdom (Haematological Malignancy Research Network, HMRN) (<xref rid="B8" ref-type="bibr">8</xref>). By contrast, we reported lower rates in comparison to France (C&#244;te d&#8217;Or) (<xref rid="B9" ref-type="bibr">9</xref>), to the United States 2016 projected incidence (<xref rid="B14" ref-type="bibr">14</xref>), and to Australia&#8217;s data for 1982-2006 (<xref rid="B22" ref-type="bibr">22</xref>), presumably due to differences in the study periods and classification. Regarding specific entities, we reported lower rates of marginal zone lymphoma and higher rates of follicular lymphoma when comparing to the HMRN (<xref rid="B8" ref-type="bibr">8</xref>), probably due to differences in classification and different completeness of cancer registries. Similarly, we report higher rates of chronic lymphocytic leukemia/small lymphocytic lymphoma and mycosis fungoides/S&#233;zary syndrome, mainly attributable to a higher registration of indolent subtypes by REDECAN rather than a higher actual incidence in Spain. Our data also show higher rates of mantle cell lymphoma which is related to environmental and genetic risk factors like farm life, atopy, and allergy (<xref rid="B23" ref-type="bibr">23</xref>).</p><p>Incidence of LNs showed a male predominance, with the main exception of follicular lymphoma (sex ratio 0.94), also described in the literature (<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>). With respect to age at diagnosis, most LNs are diagnosed at advanced ages, with a median age at diagnosis around 67 years. In line with previous studies, cases of precursor lymphoid neoplasms, Hodgkin lymphomas, and Burkitt lymphoma/leukemia were diagnosed at younger ages. In addition, we evidenced that most NOS cases are diagnosed at advanced ages, with an incidence that increases markedly after 70 years. This suggests a decrease in the quality of diagnoses in older people, since they are less likely to receive aggressive diagnostic tests due to comorbidities and/or frailty (<xref rid="B24" ref-type="bibr">24</xref>).</p><p>The global incidence trend of LN was stable during the study period in accordance with reported results of other Western countries (<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B25" ref-type="bibr">25</xref>), although significant variations were found in specific subtypes. However, the continuous update of the WHO classification of LNs across the period of study hampers the interpretation of these trends. Whilst studies have been shown that computer converted ICD-O-3 historical codes for lymphoma subtypes are generally reliable, and that such agreement is improved when those codes are grouped (<xref rid="B26" ref-type="bibr">26</xref>), some changes are hard to overcome. For instance, in 2008 the International Workshop on chronic lymphocytic leukemia changed the definition of the disease, now requiring an absolute B-cell count of 5,000 cells/&#956;L rather than the previous absolute lymphocyte count of 5,000 cells/&#956;L, which caused that many former Rai stage 0 cases now should be considered as a pre-malignant condition (monoclonal B-cell lymphocytosis) (<xref rid="B27" ref-type="bibr">27</xref>). This may explain the negative trend in the incidence of chronic lymphocytic leukemia/small lymphocytic lymphoma evidenced in our study. On the other hand, we reported a marked decrease in the incidence of NOS cases across the period of study. This might be attributed to more specific clinical diagnoses and also to improved coding in Spanish PBCRs. These improvements in coding are probably due to the training courses organized by REDECAN and given to registry professionals, in particular hematological neoplasm coding courses held during the study period.</p><p>As expected, 5y-NS was widely different across LNs subtypes, and our results are broadly consistent with those reported by specialized registries in the UK (<xref rid="B8" ref-type="bibr">8</xref>), France (<xref rid="B9" ref-type="bibr">9</xref>), and in European (HAEMACARE, EUROCARE-5) (<xref rid="B11" ref-type="bibr">11</xref>&#8211;<xref rid="B13" ref-type="bibr">13</xref>) and North American datasets (<xref rid="B28" ref-type="bibr">28</xref>). However, the survival estimates that we present are higher than those reported by studies using the HAEMACARE database (<xref rid="B11" ref-type="bibr">11</xref>). These differences can be due to the HAEMACARE&#8217;s study period (2000&#8211;2002), prior to the appearance of new treatment lines and more accurate diagnostic techniques that significantly improved survival, and to the use of the Hakulinen method for estimating survival instead of the Pohar-Perme method (<xref rid="B29" ref-type="bibr">29</xref>). By contrast, our results for most subtypes were lower than those presented by the HMRN (<xref rid="B8" ref-type="bibr">8</xref>).</p><p>Overall, survival rates differed considerably across age-groups, a well-established prognostic factor for most cancers (<xref rid="B30" ref-type="bibr">30</xref>). The poor survival of elderly patients with LN is mainly attributed to the presence of comorbidities or to their frail status, which hampers firstly, seeking for a specific diagnosis, and subsequently, the application of several treatment protocols, such as several chemotherapy regimens or stem-cell transplantation (<xref rid="B31" ref-type="bibr">31</xref>&#8211;<xref rid="B33" ref-type="bibr">33</xref>). On the other hand, we evidenced differences in the survival of mature B, T and NK-cell neoplasms between sexes that would be related to the impact of chromosomal and hormonal control of immunity (<xref rid="B34" ref-type="bibr">34</xref>), among other factors, and its consequent cancer evolution and response to treatment (<xref rid="B35" ref-type="bibr">35</xref>, <xref rid="B36" ref-type="bibr">36</xref>). Finally, NS for all LNs improved significantly during the period of study, which was mostly attributed to a better prognosis of mature B-cell neoplasms, particularly in plasma cell neoplasms and mantle cell lymphoma. This could be related to changes in treatment patterns, such the introduction of rituximab during 2004-2005 for mantle cell lymphoma, and the application of novel agents (thalidomide, bortezomib, lenalidomide) together with autologous stem cell transplantation in 2009 for multiple myeloma (<xref rid="B37" ref-type="bibr">37</xref>, <xref rid="B38" ref-type="bibr">38</xref>). The favorable effect on survival of these therapeutic changes were also reported by European PBCRs (<xref rid="B39" ref-type="bibr">39</xref>&#8211;<xref rid="B41" ref-type="bibr">41</xref>).</p><p>According to our projections, we expect 17,926 new cases of LNs in 2023. However, these data take into account neither the changes in the WHO classification (new updates were launched in 2016 and 2022) (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B6" ref-type="bibr">6</xref>), nor the impact of coronavirus disease 19 (COVID-19). Regarding the latter, according to multiple studies, the COVID-19 pandemic may have caused significant delays in diagnosis and initiation of treatment in many cancer sites. This may lead to a subsequent increase in the number of cases diagnosed in more advanced stages, with implications on survival, quality of life, and economic costs (<xref rid="B42" ref-type="bibr">42</xref>&#8211;<xref rid="B44" ref-type="bibr">44</xref>). Finally, the projections presented here could be underestimated due to the continuous improvement in the capture of hematological neoplasms by PBCRs and the development in recent years of more effective diagnostic tools. However, the methods and strategy used in data analysis provide a reasonably accurate estimate of the current incidence of LNs in Spain, based on the greatest population coverage currently provided by cancer registries in this country.</p><p>Some limitations must be considered when interpreting our data. First, changes in the classifications and diagnostic criteria of the subtypes studied hamper the interpretation of our results, as well as comparisons with previous studies. In addition, lack of homogeneity among REDECAN registries, since there is no centralized pathology and clinical review, can lead to problems of quality and completeness. For instance, this may have implications in the percentage of NOS cases in all provinces or affect the estimates of subtypes such as chronic lymphocytic leukemia or Waldenstr&#246;m&#8217;s macroglobulinemia, which have been shown to be underreported by PBCR. Nonetheless, during the last years, REDECAN has implemented training programs to improve the coding and registering of hematological neoplasms in non-specialized Spanish registries, following the example of the French Network of Cancer Registries (FRANCIM) (<xref rid="B45" ref-type="bibr">45</xref>). In addition, some LNs subtypes, such as mature T-cell and NK-cell neoplasms, are exceptionally rare; therefore, our estimates may be less robust for those entities. Finally, lack on information on disease stage at diagnosis and therapeutic patterns makes interpretation of survival rates difficult. High-resolution studies collecting such data would provide further evidence on the effectiveness of new treatments, as well as to explain geographic variations across Europe (<xref rid="B12" ref-type="bibr">12</xref>).</p></sec><sec sec-type="conclusions" id="s5"><title>Conclusions</title><p>This study presents the most comprehensive population-based analysis of LNs incidence and survival in Spain. It features some useful points for public health authorities and clinicians, such as the evolution of the incidence of several subtypes, and the expected cases in 2023 based on these data. Survival for all cases as a whole improved along the period of study, although rates are still poor for several subtypes. This study also provides information on the quality of the registries, suggesting, with a negative trend of NOS cases, improvements in the registration and/or a more specific diagnosis, although there is still room for improvement.</p></sec><sec sec-type="data-availability" id="s6"><title>Data availability statement</title><p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.</p></sec><sec id="s7"><title>REDECAN Working Group</title><p>REDECAN Working Group: Girona Cancer Registry &#8211; Coordination of hematology neoplasms in REDECAN: RM-G, Montse Puigdemont, Anna Vidal Vila, AS, Andr&#233;s Castillo-Bonilla; Tarragona Cancer Registry &#8211; Data coordination in REDECAN: MC, AA, CP, and JG; &#193;lava Cancer Registry: AL-d-M, Patricia Sancho, Mar&#237;a Luisa Iruretagoyena<bold>;</bold> Albacete Cancer Registry: Cristina Ram&#237;rez; Asturias Cancer Registry: SM, Virginia Men&#233;ndez Garc&#237;a, Marta Rodr&#237;guez Camblor; Bizkaia Cancer Registry: Visitaci&#243;n de Castro, Marta De La Cruz, Joseba Bidaurrazaga; Castell&#243;n Cancer Registry: Consol Sabater Gregori, Isabel S&#225;ez Lloret, Ana Vizca&#237;no Batll&#233;s, Xavier Pe&#241;alver Herrero; Ciudad Real Cancer Registry: CD-d-C; Cuenca Cancer Registry: AM, Rosario Jimenez Chillar&#243;n; Gipuzkoa Cancer Registry: AA; Gran Canaria Cancer Registry: MDR, Emilio De Miguel, Mar&#237;a Carmen Gabas<italic toggle="yes">;</italic> Granada Cancer Registry: MJS, Daysi Yoe-Ling Chang-Chan; Miguel Rodr&#237;guez Barranco; La Rioja Cancer Registry: Mar&#237;a Isabel Palacios, Enrique Ramalle; Mallorca Cancer Registry: Paula Franch, Patricia Ruiz Armengol, Carmen S&#225;nchez Contador; Murcia Cancer Registry: MDC, Antonia S&#225;nchez Gil, Ricardo Jos&#233; Vaamonde; Navarra Cancer Registry: MG, Eva Ardanaz; Tenerife Cancer Registry: MAA, Leonor Olga Vel&#225;zquez, Mar&#237;a Magdalena Ramos Marrero; Castilla y Le&#243;n Cancer Registry: Pilar Guti&#233;rrez, Rufino &#193;lamo, Lorena Est&#233;vez; Registro Espa&#241;ol de Tumores Infantiles: Adela Ca&#241;ete, Elena Pardo, Rafael Peris Bonet; Registro de Tumores Infantiles y Adolescentes de la Comunitat Valenciana: Consol Sabater Gregori, Ana Vizcaino Batll&#233;s, Fernando Almela Vich.</p></sec><sec sec-type="author-contributions" id="s8"><title>Author contributions</title><p>RM-G, MS, and CP contributed to the study conception and design. Data collection was performed by CP, AS, MC, MDR, MAA, IS-L, CD-d-C, AIM-N, LS-d-A, AA-A, AL-d-M, MJS, JP, PF, MDC, MG, JG, SM, and RM-G. Data analysis was performed by AA and AS. The first draft of the manuscript was written by CP. All authors contributed to the article and approved the submitted version.</p></sec><sec sec-type="funding-information" id="s9"><title>Funding</title><p>This work was partially funded by the Josep Carreras Leukaemia Research Institute (Grant No.: FIJC1100).</p></sec><sec sec-type="COI-statement" id="s10"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="disclaimer" id="s11"><title>Publisher&#8217;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec></body><back><sec sec-type="supplementary-material" id="s12"><title>Supplementary material</title><p>The Supplementary Material for this article can be found online at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.frontiersin.org/articles/10.3389/fonc.2022.1046307/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fonc.2022.1046307/full#supplementary-material</ext-link>
</p><supplementary-material id="SM1" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="DataSheet_1.xlsx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sung</surname><given-names>H</given-names></name><name name-style="western"><surname>Ferlay</surname><given-names>J</given-names></name><name name-style="western"><surname>Siegel</surname><given-names>RL</given-names></name><name name-style="western"><surname>Laversanne</surname><given-names>M</given-names></name><name name-style="western"><surname>Soerjomataram</surname><given-names>I</given-names></name><name name-style="western"><surname>Jemal</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title>. <source>CA Cancer J Clin</source> (<year>2021</year>) <volume>71</volume>(<issue>3</issue>):<page-range>209&#8211;49</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.3322/caac.21660</pub-id><pub-id pub-id-type="pmid">33538338</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jaffe</surname><given-names>ES</given-names></name><name name-style="western"><surname>Harris</surname><given-names>NL</given-names></name><name name-style="western"><surname>Stein</surname><given-names>H</given-names></name><name name-style="western"><surname>Isaacson</surname><given-names>PG</given-names></name></person-group>. <article-title>Classification of lymphoid neoplasms: the microscope as a tool for disease discovery</article-title>. <source>Blood</source> (<year>2008</year>) <volume>112</volume>:<page-range>4384&#8211;99</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1182/blood-2008-07-077982</pub-id><pub-id pub-id-type="pmcid">PMC2954680</pub-id><pub-id pub-id-type="pmid">19029456</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Jaffe</surname><given-names>ES</given-names></name><name name-style="western"><surname>Harris</surname><given-names>NL</given-names></name><name name-style="western"><surname>Stein</surname><given-names>H</given-names></name><name name-style="western"><surname>Wardiman</surname><given-names>JW</given-names></name></person-group>. <source>WHO classification of tumours of haematopoietic and lymphoid tissues</source>. <publisher-loc>Lyon, France</publisher-loc>: <publisher-name>IARC Press</publisher-name> (<year>2001</year>).</mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Swerdlow</surname><given-names>SH</given-names></name><name name-style="western"><surname>Campo</surname><given-names>E</given-names></name><name name-style="western"><surname>Harris</surname><given-names>NL</given-names></name><name name-style="western"><surname>Jaffe</surname><given-names>ES</given-names></name><name name-style="western"><surname>Pileri</surname><given-names>SA</given-names></name><name name-style="western"><surname>Stein</surname><given-names>H</given-names></name></person-group><etal/><collab>World Health Organization Classification of Tumours of haematopoietic and lymphoid tissues. Bosman FT, Jaffe ES, Lakhani SR, Ohgaki H, editors. Lyon, France: IARC (2008)</collab>.</mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Swerdlow</surname><given-names>SH</given-names></name><name name-style="western"><surname>Campo</surname><given-names>E</given-names></name><name name-style="western"><surname>Harris</surname><given-names>NL</given-names></name><name name-style="western"><surname>Jaffe</surname><given-names>ES</given-names></name><name name-style="western"><surname>Pileri</surname><given-names>SA</given-names></name><name name-style="western"><surname>Stein</surname><given-names>H,TJ</given-names></name><etal/></person-group>. <article-title>Classification of tumours of haematopoietic and lymphoid tissues</article-title>. In: <source>World health organization classification of tumours</source>, <edition>4th Edition</edition>, vol. <volume>Volume 2</volume>. . <publisher-loc>Lyon, France</publisher-loc>: <publisher-name>IARC</publisher-name> (<year>2016</year>).</mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cree</surname><given-names>IA</given-names></name></person-group>. <article-title>The WHO classification of haematolymphoid tumours</article-title>. <source>Leukemia</source> (<year>2022</year>) <volume>36</volume>(<issue>7</issue>):<fpage>1701</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/S41375-022-01625-X</pub-id><pub-id pub-id-type="pmid">35732830</pub-id><pub-id pub-id-type="pmcid">PMC9252902</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fritz</surname><given-names>A</given-names></name><name name-style="western"><surname>Percy</surname><given-names>C</given-names></name><name name-style="western"><surname>Jack</surname><given-names>A</given-names></name><name name-style="western"><surname>Shanmugaratnam</surname><given-names>K</given-names></name><name name-style="western"><surname>Sobin</surname><given-names>L</given-names></name><name name-style="western"><surname>Parkin</surname><given-names>DM</given-names></name><etal/></person-group>. <article-title>International classification of diseases for oncology, third edition</article-title>. <source>World Health Organ</source> (<year>2000</year>).</mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>A</given-names></name><name name-style="western"><surname>Crouch</surname><given-names>S</given-names></name><name name-style="western"><surname>Lax</surname><given-names>S</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Painter</surname><given-names>D</given-names></name><name name-style="western"><surname>Howell</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK's haematological malignancy research network</article-title>. <source>Br J Cancer</source> (<year>2015</year>) <volume>112</volume>(<issue>9</issue>):<page-range>1575&#8211;84</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/bjc.2015.94</pub-id><pub-id pub-id-type="pmcid">PMC4453686</pub-id><pub-id pub-id-type="pmid">25867256</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dandoit</surname><given-names>M</given-names></name><name name-style="western"><surname>Mounier</surname><given-names>M</given-names></name><name name-style="western"><surname>Guy</surname><given-names>J</given-names></name><name name-style="western"><surname>Petrella</surname><given-names>T</given-names></name><name name-style="western"><surname>Girard</surname><given-names>S</given-names></name><name name-style="western"><surname>Casasnovas</surname><given-names>RO</given-names></name><etal/></person-group>. <article-title>The heterogeneity of changes in incidence and survival among lymphoid malignancies in a 30-year French population-based registry</article-title>. <source>Leuk Lymphoma</source> (<year>2015</year>) <volume>56</volume>(<issue>4</issue>):<page-range>1050&#8211;7</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.3109/10428194.2014.956315</pub-id><pub-id pub-id-type="pmid">25166007</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sant</surname><given-names>M</given-names></name><name name-style="western"><surname>Allemani</surname><given-names>C</given-names></name><name name-style="western"><surname>Tereanu</surname><given-names>C</given-names></name><name name-style="western"><surname>de Angelis</surname><given-names>R</given-names></name><name name-style="western"><surname>Capocaccia</surname><given-names>R</given-names></name><name name-style="western"><surname>Visser</surname><given-names>O</given-names></name><etal/></person-group>. <article-title>Incidence of hematologic malignancies in Europe by morphologic subtype: Results of the HAEMACARE project</article-title>. <source>Blood</source> (<year>2010</year>) <volume>116</volume>(<issue>19</issue>):<page-range>3724&#8211;34</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1182/blood-2010-05-282632</pub-id><pub-id pub-id-type="pmid">20664057</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marcos-Gragera</surname><given-names>R</given-names></name><name name-style="western"><surname>Allemani</surname><given-names>C</given-names></name><name name-style="western"><surname>Tereanu</surname><given-names>C</given-names></name><name name-style="western"><surname>de Angelis</surname><given-names>R</given-names></name><name name-style="western"><surname>Capocaccia</surname><given-names>R</given-names></name><name name-style="western"><surname>Maynadie</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Survival of European patients diagnosed with lymphoid neoplasms in 2000-2002: Results of the HAEMACARE project</article-title>. <source>Haematologica</source> (<year>2011</year>) <volume>96</volume>(<issue>5</issue>):<page-range>720&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.3324/haematol.2010.034264</pub-id><pub-id pub-id-type="pmcid">PMC3084919</pub-id><pub-id pub-id-type="pmid">21330324</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sant</surname><given-names>M</given-names></name><name name-style="western"><surname>Minicozzi</surname><given-names>P</given-names></name><name name-style="western"><surname>Mounier</surname><given-names>M</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>LA</given-names></name><name name-style="western"><surname>Brenner</surname><given-names>H</given-names></name><name name-style="western"><surname>Holleczek</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: Results of EUROCARE-5, a population-based study</article-title>. <source>Lancet Oncol</source> (<year>2014</year>) <volume>15</volume>(<issue>9</issue>):<page-range>931&#8211;42</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S1470-2045(14)70282-7</pub-id><pub-id pub-id-type="pmid">25030467</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Angelis</surname><given-names>R</given-names></name><name name-style="western"><surname>Minicozzi</surname><given-names>P</given-names></name><name name-style="western"><surname>Sant</surname><given-names>M</given-names></name><name name-style="western"><surname>Dal Maso</surname><given-names>L</given-names></name><name name-style="western"><surname>Brewster</surname><given-names>DH</given-names></name><name name-style="western"><surname>Osca-Gelis</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Survival variations by country and age for lymphoid and myeloid malignancies in Europe 2000-2007: Results of EUROCARE-5 population-based study</article-title>. <source>Eur J Cancer</source> (<year>2015</year>) <volume>51</volume>(<issue>15</issue>):<page-range>2254&#8211;68</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.ejca.2015.08.003</pub-id><pub-id pub-id-type="pmid">26421827</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morton</surname><given-names>LM</given-names></name><name name-style="western"><surname>Wang</surname><given-names>SS</given-names></name><name name-style="western"><surname>Devesa</surname><given-names>SS</given-names></name><name name-style="western"><surname>Hartge</surname><given-names>P</given-names></name><name name-style="western"><surname>Weisenburger</surname><given-names>DD</given-names></name><name name-style="western"><surname>Linet</surname><given-names>MS</given-names></name></person-group>. <article-title>Lymphoma incidence patterns by WHO subtype in the united states, 1992-2001</article-title>. <source>Blood</source> (<year>2006</year>) <volume>107</volume>(<issue>1</issue>):<page-range>265&#8211;76</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1182/blood-2005-06-2508</pub-id><pub-id pub-id-type="pmcid">PMC1895348</pub-id><pub-id pub-id-type="pmid">16150940</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Solans</surname><given-names>M</given-names></name><name name-style="western"><surname>F&#224;brega</surname><given-names>A</given-names></name><name name-style="western"><surname>Morea</surname><given-names>D</given-names></name><name name-style="western"><surname>Au&#241;on-Sanz</surname><given-names>C</given-names></name><name name-style="western"><surname>Granada</surname><given-names>I</given-names></name><name name-style="western"><surname>Roncero</surname><given-names>JM</given-names></name><etal/></person-group>. <article-title>Population-based incidence of lymphoid neoplasms: Twenty years of epidemiological data in the girona province, Spain</article-title>. <source>Cancer Epidemiol</source> (<year>2019</year>) <volume>58</volume>:<fpage>8</fpage>&#8211;<lpage>11</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.canep.2018.11.001</pub-id><pub-id pub-id-type="pmid">30423540</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Villavicencio</surname><given-names>A</given-names></name><name name-style="western"><surname>Solans</surname><given-names>M</given-names></name><name name-style="western"><surname>Au&#241;on-Sanz</surname><given-names>C</given-names></name><name name-style="western"><surname>Roncero</surname><given-names>JM</given-names></name><name name-style="western"><surname>Marcos-Gragera</surname><given-names>R</given-names></name></person-group>. <article-title>Population-based survival of lymphoid neoplasms: Twenty years of epidemiological data in the girona province, Spain</article-title>. <source>Cancer Epidemiol</source> (<year>2020</year>) <volume>69</volume>:<fpage>1</fpage>&#8211;<lpage>5</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.canep.2020.101841</pub-id><pub-id pub-id-type="pmid">33157510</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Spanish Network of Cancer Registries (REDECAN)</collab></person-group>. . Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.redecan.org/es">https://www.redecan.org/es</uri> (Accessed <date-in-citation content-type="access-date">June 28, 2022</date-in-citation>).</mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Instituto Nacional de Estad&#237;stica (INE)</collab></person-group>. . Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ine.es">https://www.ine.es</uri> (Accessed <date-in-citation content-type="access-date">June 22, 2022</date-in-citation>).</mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="book"><person-group person-group-type="editor"><name name-style="western"><surname>Tyczynski</surname><given-names>J</given-names></name><name name-style="western"><surname>D&#233;maret</surname><given-names>E</given-names></name><name name-style="western"><surname>Parkin</surname><given-names>D</given-names></name></person-group> eds. <source>Standards and guidelines for cancer registration in Europe: the ENCR recommendations</source>. <publisher-loc>Lyon, France</publisher-loc>: <publisher-name>IARC technical publication</publisher-name> (<year>2003</year>).</mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perme</surname><given-names>MP</given-names></name><name name-style="western"><surname>Stare</surname><given-names>J</given-names></name><name name-style="western"><surname>Est&#232;ve</surname><given-names>J</given-names></name></person-group>. <article-title>On estimation in relative survival</article-title>. <source>Biometrics</source> (<year>2012</year>) <volume>68</volume>(<issue>1</issue>):<page-range>113&#8211;20</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1111/j.1541-0420.2011.01640.x</pub-id><pub-id pub-id-type="pmid">21689081</pub-id></mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pavli&#269;</surname><given-names>K</given-names></name><name name-style="western"><surname>Perme</surname><given-names>M</given-names></name></person-group>. <article-title>On comparison of net survival curves</article-title>. <source>BMC Med Res Methodol</source> (<year>2017</year>) <volume>17</volume>:<fpage>79</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s12874-017-0351-3</pub-id><pub-id pub-id-type="pmid">28464839</pub-id><pub-id pub-id-type="pmcid">PMC5414380</pub-id></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Leeuwen</surname><given-names>MT</given-names></name><name name-style="western"><surname>Turner</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Joske</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Falster</surname><given-names>MO</given-names></name><name name-style="western"><surname>Srasuebkul</surname><given-names>P</given-names></name><name name-style="western"><surname>Meagher</surname><given-names>NS</given-names></name><etal/></person-group>. <article-title>Lymphoid neoplasm incidence by WHO subtype in Australia 1982-2006</article-title>. <source>Int J Cancer</source> (<year>2014</year>) <volume>135</volume>(<issue>9</issue>):<page-range>2146&#8211;56</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/ijc.28849</pub-id><pub-id pub-id-type="pmid">24639369</pub-id></mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smedby</surname><given-names>KE</given-names></name><name name-style="western"><surname>Sampson</surname><given-names>JN</given-names></name><name name-style="western"><surname>Turner</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Slager</surname><given-names>SL</given-names></name><name name-style="western"><surname>Maynadi&#233;</surname><given-names>M</given-names></name><name name-style="western"><surname>Roman</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Medical history, lifestyle, family history, and occupational risk factors for mantle cell lymphoma: The interlymph non-hodgkin lymphoma subtypes project</article-title>. <source>J Natl Cancer Inst Monogr</source> (<year>2014</year>) <volume>48</volume>:<fpage>76</fpage>&#8211;<lpage>86</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1093/jncimonographs/lgu007</pub-id><pub-id pub-id-type="pmcid">PMC4155462</pub-id><pub-id pub-id-type="pmid">25174028</pub-id></mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vovelle</surname><given-names>J</given-names></name><name name-style="western"><surname>Row</surname><given-names>C</given-names></name><name name-style="western"><surname>Larosa</surname><given-names>F</given-names></name><name name-style="western"><surname>Guy</surname><given-names>J</given-names></name><name name-style="western"><surname>Mihai</surname><given-names>AM</given-names></name><name name-style="western"><surname>Maynadi&#233;</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Prescription of blood lymphocyte immunophenotyping in the diagnosis of lymphoid neoplasms in older adults</article-title>. <source>J Clin Med</source> (<year>2022</year>) <volume>11</volume>(<issue>6</issue>):<elocation-id>1748</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3390/jcm11061748</pub-id><pub-id pub-id-type="pmid">35330073</pub-id><pub-id pub-id-type="pmcid">PMC8949070</pub-id></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adamson</surname><given-names>P</given-names></name><name name-style="western"><surname>Bray</surname><given-names>F</given-names></name><name name-style="western"><surname>Costantini</surname><given-names>AS</given-names></name><name name-style="western"><surname>Tao</surname><given-names>MH</given-names></name><name name-style="western"><surname>Weiderpass</surname><given-names>E</given-names></name><name name-style="western"><surname>Roman</surname><given-names>E</given-names></name></person-group>. <article-title>Time trends in the registration of Hodgkin and non-Hodgkin lymphomas in Europe</article-title>. <source>Eur J Cancer</source> (<year>2007</year>) <volume>43</volume>(<issue>2</issue>):<fpage>391</fpage>&#8211;<lpage>401</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.ejca.2006.10.008</pub-id><pub-id pub-id-type="pmid">17134891</pub-id></mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clarke</surname><given-names>CA</given-names></name><name name-style="western"><surname>Undurraga</surname><given-names>DM</given-names></name><name name-style="western"><surname>Harasty</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Glaser</surname><given-names>SL</given-names></name><name name-style="western"><surname>Morton</surname><given-names>LM</given-names></name><name name-style="western"><surname>Holly</surname><given-names>EA</given-names></name></person-group>. <article-title>Changes in cancer registry coding for lymphoma subtypes: Reliability over time and relevance for surveillance and study</article-title>. <source>Cancer Epidemiol Biomarkers Prev</source> (<year>2006</year>) <volume>15</volume>(<issue>4</issue>):<page-range>630&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1158/1055-9965.EPI-05-0549</pub-id><pub-id pub-id-type="pmid">16614102</pub-id></mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Call</surname><given-names>TG</given-names></name><name name-style="western"><surname>Norman</surname><given-names>AD</given-names></name><name name-style="western"><surname>Hanson</surname><given-names>CA</given-names></name><name name-style="western"><surname>Achenbach</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Kay</surname><given-names>NE</given-names></name><name name-style="western"><surname>Zent</surname><given-names>CS</given-names></name><etal/></person-group>. <article-title>Incidence of chronic lymphocytic leukemia and high-count monoclonal b-cell lymphocytosis using the 2008 guidelines</article-title>. <source>Cancer</source> (<year>2014</year>) <volume>120</volume>(<issue>13</issue>):<page-range>2000&#8211;5</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/cncr.28690</pub-id><pub-id pub-id-type="pmcid">PMC4124730</pub-id><pub-id pub-id-type="pmid">24711224</pub-id></mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Teras</surname><given-names>LR</given-names></name><name name-style="western"><surname>DeSantis</surname><given-names>CE</given-names></name><name name-style="western"><surname>Cerhan</surname><given-names>JR</given-names></name><name name-style="western"><surname>Morton</surname><given-names>LM</given-names></name><name name-style="western"><surname>Jemal</surname><given-names>A</given-names></name><name name-style="western"><surname>Flowers</surname><given-names>CR</given-names></name></person-group>. <article-title>US Lymphoid malignancy statistics by world health organization subtypes</article-title>. <source>CA Cancer J Clin</source> (<year>2016</year>) <volume>66</volume>(<issue>6</issue>):<page-range>443&#8211;59</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.3322/caac.21357</pub-id><pub-id pub-id-type="pmid">27618563</pub-id></mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roche</surname><given-names>L</given-names></name><name name-style="western"><surname>Danieli</surname><given-names>C</given-names></name><name name-style="western"><surname>Belot</surname><given-names>A</given-names></name><name name-style="western"><surname>Grosclaude</surname><given-names>P</given-names></name><name name-style="western"><surname>Bouvier</surname><given-names>AM</given-names></name><name name-style="western"><surname>Velten</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Cancer net survival on registry data: Use of the new unbiased pohar-perme estimator and magnitude of the bias with the classical methods</article-title>. <source>Int J Cancer</source> (<year>2013</year>) <volume>132</volume>(<issue>10</issue>):<page-range>2359&#8211;69</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/ijc.27830</pub-id><pub-id pub-id-type="pmid">22961565</pub-id></mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guevara</surname><given-names>M</given-names></name><name name-style="western"><surname>Molinuevo</surname><given-names>A</given-names></name><name name-style="western"><surname>Salmer&#243;n</surname><given-names>D</given-names></name><name name-style="western"><surname>Marcos-Gragera</surname><given-names>R</given-names></name><name name-style="western"><surname>Carulla</surname><given-names>M</given-names></name><name name-style="western"><surname>Chirlaque</surname><given-names>M-D</given-names></name><etal/></person-group>. <article-title>Cancer survival in adults in Spain: A population-based study of the Spanish network of cancer registries (REDECAN)</article-title>. <source>Cancers</source> (<year>2022</year>) <volume>14</volume>(<issue>10</issue>):<elocation-id>2441</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3390/cancers14102441</pub-id><pub-id pub-id-type="pmid">35626046</pub-id><pub-id pub-id-type="pmcid">PMC9139549</pub-id></mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cordoba</surname><given-names>R</given-names></name><name name-style="western"><surname>Eyre</surname><given-names>TA</given-names></name><name name-style="western"><surname>Klepin</surname><given-names>HD</given-names></name><name name-style="western"><surname>Wildes</surname><given-names>TM</given-names></name><name name-style="western"><surname>Goede</surname><given-names>V</given-names></name></person-group>. <article-title>A comprehensive approach to therapy of haematological malignancies in older patients</article-title>. <source>Lancet Haematol</source> (<year>2021</year>) <volume>8</volume>(<issue>11</issue>):<page-range>840&#8211;52</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S2352-3026(21)00241-6</pub-id><pub-id pub-id-type="pmid">34624238</pub-id></mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scheepers</surname><given-names>ERM</given-names></name><name name-style="western"><surname>Vondeling</surname><given-names>AM</given-names></name><name name-style="western"><surname>Thielen</surname><given-names>N</given-names></name><name name-style="western"><surname>van der Griend</surname><given-names>R</given-names></name><name name-style="western"><surname>Stauder</surname><given-names>R</given-names></name><name name-style="western"><surname>Hamaker</surname><given-names>ME</given-names></name></person-group>. <article-title>Geriatric assessment in older patients with a hematologic malignancy: A systematic review</article-title>. <source>Haematologica</source> (<year>2020</year>) <volume>105</volume>(<issue>6</issue>):<page-range>1484&#8211;93</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.3324/haematol.2019.245803</pub-id><pub-id pub-id-type="pmcid">PMC7271571</pub-id><pub-id pub-id-type="pmid">32381581</pub-id></mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krok-Schoen</surname><given-names>JL</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>JL</given-names></name><name name-style="western"><surname>Stephens</surname><given-names>JA</given-names></name><name name-style="western"><surname>Mims</surname><given-names>A</given-names></name><name name-style="western"><surname>Ayyappan</surname><given-names>S</given-names></name><name name-style="western"><surname>Woyach</surname><given-names>JA</given-names></name><etal/></person-group>. <article-title>Incidence and survival of hematological cancers among adults ages &#8805;75 years</article-title>. <source>Cancer Med</source> (<year>2018</year>) <volume>7</volume>(<issue>7</issue>):<page-range>3425&#8211;33</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/cam4.1461</pub-id><pub-id pub-id-type="pmcid">PMC6051144</pub-id><pub-id pub-id-type="pmid">29654631</pub-id></mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ben-Batalla</surname><given-names>I</given-names></name><name name-style="western"><surname>Vargas-Delgado</surname><given-names>ME</given-names></name><name name-style="western"><surname>Meier</surname><given-names>L</given-names></name><name name-style="western"><surname>Loges</surname><given-names>S</given-names></name></person-group>. <article-title>Sexual dimorphism in solid and hematological malignancies</article-title>. <source>Semin Immunopathol</source> (<year>2019</year>) <volume>41</volume>(<issue>2</issue>):<page-range>251&#8211;63</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s00281-018-0724-7</pub-id><pub-id pub-id-type="pmid">30361802</pub-id></mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haupt</surname><given-names>S</given-names></name><name name-style="western"><surname>Caramia</surname><given-names>F</given-names></name><name name-style="western"><surname>Klein</surname><given-names>SL</given-names></name><name name-style="western"><surname>Rubin</surname><given-names>JB</given-names></name><name name-style="western"><surname>Haupt</surname><given-names>Y</given-names></name></person-group>. <article-title>Sex disparities matter in cancer development and therapy</article-title>. <source>Nat Rev Cancer</source> (<year>2021</year>) <volume>21</volume>(<issue>6</issue>):<fpage>393</fpage>&#8211;<lpage>407</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41568-021-00348-y</pub-id><pub-id pub-id-type="pmid">33879867</pub-id><pub-id pub-id-type="pmcid">PMC8284191</pub-id></mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klein</surname><given-names>SL</given-names></name><name name-style="western"><surname>Flanagan</surname><given-names>KL</given-names></name></person-group>. <article-title>Sex differences in immune responses</article-title>. <source>Nat Rev Immunol</source> (<year>2016</year>) <volume>16</volume>(<issue>10</issue>):<page-range>626&#8211;38</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/nri.2016.90</pub-id><pub-id pub-id-type="pmid">27546235</pub-id></mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brenner</surname><given-names>H</given-names></name><name name-style="western"><surname>Gondos</surname><given-names>A</given-names></name><name name-style="western"><surname>Pulte</surname><given-names>D</given-names></name></person-group>. <article-title>Recent major improvement in long-term survival of younger patients with multiple myeloma</article-title>. <source>Blood</source> (<year>2008</year>) <volume>111</volume>(<issue>5</issue>):<page-range>2521&#8211;6</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1182/blood-2007-08-104984</pub-id><pub-id pub-id-type="pmid">17901246</pub-id></mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moreau</surname><given-names>P</given-names></name><name name-style="western"><surname>Avet-Loiseau</surname><given-names>H</given-names></name><name name-style="western"><surname>Harousseau</surname><given-names>JL</given-names></name><name name-style="western"><surname>Attal</surname><given-names>M</given-names></name></person-group>. <article-title>Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies</article-title>. <source>J Clin Oncol</source> (<year>2011</year>) <volume>29</volume>(<issue>14</issue>):<page-range>1898&#8211;906</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1200/JCO.2010.32.5878</pub-id><pub-id pub-id-type="pmid">21482979</pub-id></mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>A</given-names></name><name name-style="western"><surname>Roman</surname><given-names>E</given-names></name><name name-style="western"><surname>Appleton</surname><given-names>S</given-names></name><name name-style="western"><surname>Howell</surname><given-names>D</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>R</given-names></name><name name-style="western"><surname>Burton</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Impact of novel therapies for mantle cell lymphoma in the real world setting: a report from the UK's haematological malignancy research network (HMRN)</article-title>. <source>Br J Haematol</source> (<year>2018</year>) <volume>181</volume>(<issue>2</issue>):<page-range>215&#8211;28</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1111/bjh.15170</pub-id><pub-id pub-id-type="pmcid">PMC5947165</pub-id><pub-id pub-id-type="pmid">29532919</pub-id></mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blimark</surname><given-names>CH</given-names></name><name name-style="western"><surname>Turesson</surname><given-names>I</given-names></name><name name-style="western"><surname>Genell</surname><given-names>A</given-names></name><name name-style="western"><surname>Ahlberg</surname><given-names>L</given-names></name><name name-style="western"><surname>Bj&#246;rkstrand</surname><given-names>B</given-names></name><name name-style="western"><surname>Carlson</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Outcome and survival of myeloma patients diagnosed 2008-2015. real-world data on 4904 patients from the Swedish myeloma registry</article-title>. <source>Haematologica</source> (<year>2018</year>) <volume>103</volume>(<issue>3</issue>):<page-range>506&#8211;13</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.3324/haematol.2017.178103</pub-id><pub-id pub-id-type="pmcid">PMC5830385</pub-id><pub-id pub-id-type="pmid">29217784</pub-id></mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang-Chan</surname><given-names>DY</given-names></name><name name-style="western"><surname>R&#237;os-Tamayo</surname><given-names>R</given-names></name><name name-style="western"><surname>Rodr&#237;guez Barranco</surname><given-names>M</given-names></name><name name-style="western"><surname>Redondo-S&#225;nchez</surname><given-names>D</given-names></name><name name-style="western"><surname>Gonz&#225;lez</surname><given-names>Y</given-names></name><name name-style="western"><surname>Marcos-Gragera</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Trends of incidence, mortality and survival of multiple myeloma in spain. a twenty-three-year population-based study</article-title>. <source>Clin Transl Oncol</source> (<year>2021</year>) <volume>23</volume>(<issue>7</issue>):<page-range>1429&#8211;39</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s12094-020-02541-1</pub-id><pub-id pub-id-type="pmid">33433836</pub-id></mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanvisens</surname><given-names>A</given-names></name><name name-style="western"><surname>Ameijide</surname><given-names>A</given-names></name><name name-style="western"><surname>Carulla</surname><given-names>M</given-names></name><name name-style="western"><surname>Marcos-Gragera</surname><given-names>R</given-names></name><collab>Study of the Spanish Network of Cancer Registries (REDECAN)</collab></person-group>. <article-title>En representaci&#243;n de la red espa&#241;ola de registros de c&#225;ncer (REDECAN). estimates of the incidence of hematological neoplasms in Spain, 2021</article-title>. <source>Med Clin (Barc)</source> (<year>2022</year>) <volume>158</volume>(<issue>6</issue>):<page-range>284&#8211;90</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/J.MEDCLI.2021.09.035</pub-id><pub-id pub-id-type="pmid">34949449</pub-id></mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petrova</surname><given-names>D</given-names></name><name name-style="western"><surname>P&#233;rez-G&#243;mez</surname><given-names>B</given-names></name><name name-style="western"><surname>Poll&#225;n</surname><given-names>M</given-names></name><name name-style="western"><surname>S&#225;nchez</surname><given-names>MJ</given-names></name></person-group>. <article-title>Implicaciones de la pandemia por COVID-19 sobre el c&#225;ncer en espa&#241;a [Implications of the COVID-19 pandemic for cancer in Spain]</article-title>. <source>Med Clin (Barc)</source> (<year>2020</year>) <volume>155</volume>(<issue>6</issue>):<page-range>263&#8211;6</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.medcli.2020.04.011</pub-id><pub-id pub-id-type="pmcid">PMC7205671</pub-id><pub-id pub-id-type="pmid">32444323</pub-id></mixed-citation></ref><ref id="B44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maringe</surname><given-names>C</given-names></name><name name-style="western"><surname>Spicer</surname><given-names>J</given-names></name><name name-style="western"><surname>Morris</surname><given-names>M</given-names></name><name name-style="western"><surname>Purushotham</surname><given-names>A</given-names></name><name name-style="western"><surname>Nolte</surname><given-names>E</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study</article-title>. <source>Lancet Oncol</source> (<year>2020</year>) <volume>21</volume>(<issue>8</issue>):<page-range>1023&#8211;34</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S1470-2045(20)30388-0</pub-id><pub-id pub-id-type="pmcid">PMC7417808</pub-id><pub-id pub-id-type="pmid">32702310</pub-id></mixed-citation></ref><ref id="B45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Monnereau</surname><given-names>A</given-names></name><name name-style="western"><surname>Troussard</surname><given-names>X</given-names></name><name name-style="western"><surname>Belot</surname><given-names>A</given-names></name><name name-style="western"><surname>Guizard</surname><given-names>AV</given-names></name><name name-style="western"><surname>Woronoff</surname><given-names>AS</given-names></name><name name-style="western"><surname>Bara</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Unbiased estimates of long-term net survival of hematological malignancy patients detailed by major subtypes in France</article-title>. <source>Int J Cancer</source> (<year>2013</year>) <volume>132</volume>(<issue>10</issue>):<page-range>2378&#8211;87</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/ijc.27889</pub-id><pub-id pub-id-type="pmid">23034773</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>